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Background: Due to the high association with mortality and morbidity, carbapenem-resistant 
Enterobacterales (CRE) in general, and carbapenem-resistant Klebsiella pneumoniae, in 
particular, have been listed as high-priority pathogens by the World Health Organization (WHO) 
for the research and development of new antibiotics. Concomitant resistance to multiple antibiotics 
of different classes, impedes efficient clinical management of CRE infections. We characterized 
carbapenemase-producing K. pneumoniae (CPKP) isolates from sequential rectal screening of 
patients in a single intensive care unit (ICU) in a public hospital in the uMgungundlovu District of 
Kwazulu-Natal, South Africa, collected over one month. Method: Ninety-seven rectal swabs 
collected from consenting adult patients (n=31) on day 1, 3, 7 and weekly thereafter were screened 
for carbapenemase-production using Chrome-ID selective media. Fourteen CPKP were subjected 
to speciation and antibiotic susceptibility testing using the VITEK 2® automated system and their 
clonality was ascertained by ERIC/PCR. A sub-sample of eight isolates from five patients 
underwent whole genome sequencing (WGS) on the Illumina MiSeq platform followed by 
bioinformatics analysis to delineate the resistome, virulome, mobilome, clonality and 
phylogeography. Results: All isolates (100%) were resistant to ertapenem and meropenem and 
71.4% (n=10) were resistant to imipenem. All isolates harbored the blaOXA-181 carbapenemase 
(100%, n=8) and also carried other β-lactamase genes such as OXA-1, CTX-M-15, TEM-1B and 
SHV-1. IncF, IncX3, and Col plasmid replicons groups and class I integrons (ln191 and ln27) were 
detected. All isolates belonged to the same sequence type ST307 and capsular serotypes (K102, 
O2v2) and several were associated with a single bed located in the ICU. All but one isolate carried 
the same plasmid multilocus sequence type [K7:A-:B-] and the same virulence repertoire was 
identified reflecting the epidemiological relationships between isolates. BlaOXA-181 were 
presumably located on a multi-replicon plasmid similar to that of E. coli p010_B-OXA181, and 
isolates were aligned with several South African and international clades, demonstrating horizontal 
and vertical transboundary distribution. Conclusion: OXA-181-producing K. pneumoniae 
belonging to ST307 was found to be potentially endemic in the hospital ICU environment of a 
public hospital in KwaZulu-Natal South Africa. The presence of a myriad of antibiotic resistance 
genes (ARGs) and mobile genetic elements (MGEs) in different permutations and combinations 
presents challenges to clinical management and infection prevention and control measures. This 
xiv 
 
necessitates a CRE screening programme and strict infection prevention and control measures to 
detect and eliminate this endemic clone
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Molecular Epidemiology of Carbapenem-Resistant Enterobacterales Colonization 
in an Intensive Care Unit 
CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Agents that can eradicate or inhibit bacterial growth are known as antibiotics, with their life-saving 
advantages hailed after penicillin's first clinical use in the 1940s (Munita and Arias, 2016). The 
efficacy of antibiotics has dwindled because of the steady increase in bacterial resistance, a 
situation exacerbated by very few new antibiotics in the pipeline to replace the current antibiotics 
against which resistance has evolved (World Health Organization, 2014; Codjoe and Donkor, 
2018). 
Carbapenems are β-lactam antibiotics that are among the most effective antibiotics against Gram-
positive and Gram-negative bacteria, providing a broad spectrum of antibacterial activity. Their 
molecular structure, along with β-lactam ring, gives added stability to most β-lactamases and 
extended-spectrum β-lactamases (ESBLs) (Meletis, 2016). Carbapenems are thus often considered 
"last-resort antibiotics" or "last-line agents" when critically ill patients are suspected of harbouring 
multi-drug resistant (MDR) bacteria (Ramsamy et al., 2020). The frequent use of carbapenems has 
allowed the evolution of carbapenem resistance, most commonly caused by carbapenemases which 
are β-lactamases capable of hydrolysing carbapenems (Pitout, Nordmann and Poirel, 2015). The 
Ambler classification method allows for the differentiation of carbapenemases into class A (e.g., 
KPC, SME, IMI, and GES), class B (e.g., NDM, VIM, and IMP), and class D (OXA-48-like). The 
carbapenemases of class A and class D are serine β-lactamases, and the carbapenemases of class 
B are metallo-β-lactamases (MBLs) (Cui, Zhang and Du, 2019). 
Carbapenem-resistant Enterobacterales (CRE) are listed by the World Health Organization 
(WHO) as high priority for the research and development of new antibiotics (World Health 
Organization, 2017). Serious CRE infections have a higher risk of fatality than those caused by 
carbapenem-sensitive isolates (Martin et al., 2018). This threat is considerably higher when the 
carbapenem resistance in Enterobacterales is due to carbapenemase production (CPEs). Compared 
with the non-CPE infections (n=37,45%), CPE infections (n=46, 55%) were reported to cause four 
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times the risk of death within 14 days among hospitalized patients in an academic hospital in the 
USA between March 2013 and April 2016 (Tamma et al., 2017). 
This study describes the molecular epidemiology of CPE colonization in patients from an intensive 
care unit (ICU) in a single public hospital in the KwaZulu-Natal area using whole-genome 
sequencings (WGS) and bioinformatics analysis. Delineating the molecular signatures of CPEs 
will direct containment strategies to improve patient outcomes. 
1.2 Literature review 
1.2.1 Antibiotics 
Substances that interfere with the growth of micro-organisms (bacteria, viruses, fungi, and 
parasites) are called antimicrobial agents and act at concentrations that are tolerated by the hosts 
which they inhabit/infect (Balouiri, Sadiki and Ibnsouda, 2016). Antibiotics are a subdivision of 
antimicrobial agents that are produced wholly, or partially, by fermentation by micro-organisms 
and chemical synthesis to suppress the growth of or kill bacteria. Examples of antibiotics are 
penicillins and cephalosporins from moulds, polymyxins and bacitracin from bacteria, and 
aminoglycosides from actinomyces (Nemeth, Oesch and Kuster, 2015). Most of the antibiotics 
used in clinics today are from natural sources detected using variants of the Waksman platform 
strategy in the environmental material screens (Maarten et al., 2018). Synthetic antibiotics were 
traced back toward Paul Ehrlich, who identified different chemicals such as salvarsan involved in 
the syphilis treatment. Later, Domagk discovered the dye prontosil and its active metabolite 
sulfanilamide, which inhibited folic acid biosynthesis. This research has contributed to the 
development of sulfa drugs (Hutchings, Truman and Wilkinson, 2019). Medicinal chemistry and 
target-based compound library high-throughput screens replaced natural product studies in the 
mid-1990s and incorporated the idea of synthetic chemistry as a technique for the production of 
next-generation antibiotics. Strides in computational biology (system biology, bioinformatics, and 
metagenomics) and structural biological innovations (crystal protein target compositions, ligand 
screens by docking software, and the so-called designer drug strategy) drove synthetic biology as 
a third discovery strategy (Hoffman, 2020). 
Antibiotics can be divided into two classes; bacteriostatic, and bactericidal, in which the former 
inhibit or stop the growth and multiplication of bacteria but do not kill them like the latter, and 
killing taking place by the immune system (Nemeth, Oesch and Kuster, 2015). 
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In general, major groups of antibiotics i.e., β-lactams, aminoglycosides, tetracyclines, macrolides, 
and glycopeptides can be categorised in terms of their mechanisms of action, that is, according to 
targets of their action. Two commonly used antibiotic classes, β-lactams and glycopeptides, 
interact with extracellular cross-linking steps and weaken the peptidoglycan layer's mechanical 
strength interfering with cell wall biosynthesis, however, the former group because of their relative 
efficacy and safety are the most clinically significant group (Sekyere, Govinden and Essack, 2016; 
Walsh and Wencewicz, 2016). Another class of antibiotics, such as the lipopeptides daptomycin 
and lanthionine-containing peptides disrupt the peptidoglycan assembly process which is 
important to maintain the integrity of the cell membrane, and acts as a barrier to organize the 
passage of ions and small molecules across the cell membrane (Walsh and Wencewicz, 2016). 
Unlike the last two classes, there are other classes that block macromolecular metabolism either 
by altering the synthesis of bacterial proteins that perform many different functions of life, growth, 
and bacterial cell division. These acts either on small subunits of ribosomes (tetracyclines and 
aminoglycosides) or large subunits (erythromycins, streptograms and lincosamides). Yet another 
affects DNA replication or block transcription of DNA into RNA, e.g., processes performed with 
DNA gyrase enzyme and bacterial RNA polymerase enzymes that are inhibited by 
fluoroquinolones and rifamycin respectively (Davies and Davies, 2010; Walsh and Wencewicz, 
2016). Sulfonamide antibiotics, considered to be the fifth group, act as competitive inhibitors of 
para-amino benzoate in the maturation of folate in which DNA biosynthesis is also affected (Walsh 
and Wencewicz, 2016). 
1.2.2 Antibiotic resistance 
The life-saving benefits of antibiotics had been recognized since penicillin was first introduced in 
the 1940s (Munita and Arias, 2016). Alexander Fleming who discovered penicillin was the first 
one to emphasize that resistance would occur if antibiotics were excessively and inappropriately 
used during his 1945 Nobel Prize elocution (World Health Organization, 2014). Antibiotic 
resistance (ABR) happens when bacteria can circumvent the mechanisms that antibiotics use 
against them or develop this ability with time. Infections caused by bacteria resistant to antibiotics 
are generally more challenging to manage, can cause relapses and significant mortality rates 
(Christaki, Marcou and Tofarides, 2020). According to studies conducted worldwide, particularly 
during the last two decades, the world is moving towards the "post-antibiotic era" largely attributed 
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to the inappropriate use of antibiotics. Clinical as well as financial medical outcomes are adversely 
affected by ABR in terms of higher morbidity and mortality, extended hospital stays, increased 
healthcare costs, and expensive or higher toxic alternative therapies (Butler, Blaskovich and 
Cooper, 2017). Infectious diseases remain a dominant cause of death globally, since the antibiotics 
used to cure them are being exhausted with rising ABR. Modern medicine that is highly dependent 
on antibiotics for bone marrow and organ transplants, surgeries, treating immune-compromised 
patients and cancer patients, and normal hip and knee replacement (Cassini et al., 2019) is 
compromised because of ABR. 
Antibiotic resistance is a growing global health challenge caused by the consumption of 
antibiotics. Results from the analysis of the relationship between antibiotic use and resistance over 
time concluded from a study carried out in 76 countries in health systems around the world between 
2000 and 2015, reflected a global health crisis, especially in low- and middle-income countries 
(LMICs), that showed 2.5 times the antibiotic consumption of high-income countries (HICs). It 
underlines the need for global monitoring of antibiotic usage to inform policies to minimize 
antibiotic use and resistance while maintaining access to those life-saving drugs (Klein et al., 
2018). 
ABR develops in bacteria through many mechanisms that could be intrinsic, acquired, or adaptive. 
Intrinsic resistance is due to the bacterium's inherent characteristics. Examples include the 
resistance to glycopeptides shown by Gram-negative bacteria due to outer membrane 
impermeability (Christaki, Marcou and Tofarides, 2020). Some bacteria are known to have a 
natural resistance to the antibiotics synthesized by them and to those with similar mechanisms of 
action (Davies and Davies, 2010; Munita and Arias, 2016). Acquired resistance occurs when an 
earlier susceptible bacterium acquires a resistance mechanism by either a mutation or the 
attainment of the new genetic material of exogenous origin by horizontal gene transfer (HGT) 
(Christaki, Marcou and Tofarides, 2020). The innate ability of bacteria to divide in a few minutes 
into millions of cells can lead to daughter cells with genomes that differ from parent cells. These 
mutational changes may confer antibiotic resistance when the new genome expresses proteins that 
can protect the antibiotic binding site from being altered or broken down by an antibiotic. (Davies 
and Davies, 2010; Munita and Arias, 2016). Adaptive resistance is described as resistance toward 
individual or more antibiotics caused by involvement of a particular environmental factor (e.g., 
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pH, stress, nutrient conditions, ion concentrations, antibiotic sub-inhibitory levels). Unlike 
intrinsic or acquired resistance, adaptive resistance is temporary which makes bacteria respond 
more rapidly to antibiotics' challenge.  The adaptation reverts typically to the previous state once 
the inducing signal is removed (Lee, 2019). Modulation, particularly of the expression of efflux 
pumps and porins, is involved in developing adaptive resistance (Motta, Cluzel and Aldana, 2015). 
Resistance is can be disseminated by vertical gene transferral (VGT) to daughter cells from mother 
cells and is maintained through this form of expression in generations of bacteria. For cases where 
bacteria are exposed to sub-lethal antibiotic doses, resistance genes to these agents may grow over 
time (Wright, 2010). 
HGT can take place by three mechanisms. Transformation is genetic recombination where free 
bacterial DNA elements enter the recipient bacteria and are inserted into its chromosome. 
Transduction requires a bacteriophage transfer of genetic material (Holmes et al., 2016; Christaki, 
Marcou and Tofarides, 2020; Munita and Arias, 2016). Resistance genes also are typically 
harboured on conjugative plasmids that are mobile genetic elements (MGEs) capable of initiating 
conjugation between two bacterial cells of the same or different species by means of sex pili 
expression. During conjugation, these plasmids are transferred to other bacteria. HGT has been 
described as being an important factor in the spread of antibiotic resistance (Partridge et al., 2018). 
Bacteria express various mechanisms of antibiotic resistance, including enzymatic action, by 
which bacteria can modify the chemical composition of antibiotics by means of hydrolysis (β-
lactam antibiotics), acetylation (aminoglycosides and tetracyclines), methylation, etc., making the 
antibiotic ineffective (Munita and Arias, 2016). In other cases, bacteria express target 
modifications (target replacement, target site enzymatic alterations, target position mutations, 
target position protection, excess target production, or target bypass) and decreased antibiotic 
accumulation due to lower permeability and/or enhanced efflux (Christaki, Marcou and Tofarides, 
2020). 
1.2.3 β-Lactam antibiotics 
β-lactams are well tolerated, effective and the most widely used antibiotics in clinical medicine. 
They are flexible in that they can be structurally modified to give rise to numerous active forms, a 
malleability not possessed by other antibiotic classes. β-lactams are antibiotics of choice for 
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treating bacterial infections (Bush and Bradford, 2016; Sekyere, Govinden and Essack, 2016; 
Klein et al., 2018). All have an integral four-member lactam ring that can be fused in order to form 
bicyclic ring structures or exist as isolated rings. β-Lactams, similar to other classes of antibiotics, 
have experienced continuous improvement following their initial discovery with respect to features 
such as potency, range of activity, pharmacokinetics, safety profiles, and resistance development. 
The types of substitutions added to the basic nucleus determine the activity of a particular β-lactam 
compound, e.g., substitutions in the 7-α region of cephalosporins confer enhanced stability against 
β-lactamases, while may also decrease the antibiotic activity against certain species. Replacing 
sulphur in the nucleus with oxygen can increase biological activity. The β-lactam compound's 
chemical composition is therefore a balance between biological activity, stability of β-lactamase, 
and toxicity (Davies and Davies, 2010). 
The antibacterial activity of β-lactams is derived from their similarity to the terminal D-Ala–D-
Ala subunit of the peptidoglycan stem pentapeptide, with both β-lactam amide and neighbouring 
carboxylate (or sulfonic acid in monobactams) groups resembling terminal carboxylate of D-Ala–
D-Ala and the peptide bond. The interaction of the β-lactam ring with nucleophilic serine of target 
penicillin-binding proteins (PBPs) prevents the formation of cross-linking peptidoglycan 
transpeptide (Tooke et al., 2019). This includes inactivating the transpeptidases needed for the 
bacterial cell wall synthesis terminal step. At the enzymatic active site, the PBPs, which comprise 
these transpeptidases, all have a serine that is acylated by the β-lactams in a reaction which is 
essentially irreversible within a bacterial cell. PBPs undergo fast acylation followed by gradual 
deacylation to restore active enzyme and an inactive ring-opened β-lactam, which is also 
hydrolysed (Bush and Bradford, 2019). Peptidoglycan is an integral constituent of the cell wall of 
the bacteria. The PBP structure suggests high variation among species, but it is well preserved in 
a specific bacterial genus. Alterations can enhance bacterial strength and virulence, offering 
protection from environmental stresses, natural hydrolytic enzymes, and antimicrobials. It is 
crucial to the growth and division of cells, with its net-like structure, consisting of peptide cross-
linked saccharide chains (Pazos and Peters, 2019). 
Several additional penicillin derivatives and related β-lactam groups have been discovered since 
the benzyl penicillin discovery in the 1920's. Each new class of β-lactam has been established 
either to extend its spectrum to cover additional bacterial species or to tackle varying mechanisms 
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of resistance that have emerged in the target population of bacteria, e.g. the evolution of β-
lactamases has driven the production of new β-lactams (De Angelis et al., 2020). 
Four main classes of β-lactam antibiotics are currently in clinical use. They contain three types of 
bicyclic structure: the penicillins in which the four-membered β-lactam ring fused to a thiazolidine 
ring, the cephalosporins in which the coupling component is a six-membered dihydrothiazine, and 
the carbapenems in which a five-membered pyrroline completes the bicyclic system. The 
monobactams are a fourth monocyclic β-lactam (Tooke et al., 2019). 
1.2.3.1 Penicillins 
The term 'penicillin' is commonly used to refer to various compounds with a structure based on β-
lactam ring and the same antibacterial activity as the original molecule, benzylpenicillin (penicillin 
G). For example, penicillin G is more active against Gram-positive bacteria, particularly cocci, 
several streptococci but less effective against Gram-negative bacteria (Lobanovska and Pilla, 
2017). The quest for more potent penicillins against staphylococcal β-lactamases came shortly 
after the introduction of penicillin G as the first β-lactam to be used clinically in 1940. Penicillin 
G was followed by another natural penicillin, phenoxymethyl penicillin (Penicillin V)that could 
be orally administered (Sekyere, Govinden and Essack, 2016). The classification of penicillins is 
based on chemical substitutions for residues attached to the β-lactam ring. Thereafter the second 
generation of semi-synthetic penicillins were developed to counteract penicillinase-producing 
Gram-positive strains that emerged due to excessive use of the first generation, e.g., oxacillin, 
dicloxacillin, and methicillin. The relatively limited range of these antibiotics' action with the need 
for broader coverage of Gram-negative bacteria expanded the second generation. The third 
generation of broad-spectrum penicillins, also referred to as aminopenicillins, were introduced in 
the 1960s. Examples of this group are amoxicillin and ampicillin and are more successful against 
a larger group of Gram-negative bacteria. The next generation of penicillins comprising 
carboxypenicillins and ureidopenicillins further broadened the penicillin coverage spectrum 
against Gram-negative bacteria and showed good activity against Pseudomonas aeruginosa 
(Lobanovska and Pilla, 2017). 
1.2.3.2 Cephalosporins 
In the 1950s, a new path for the production of the cephalosporins was opened with the discovery 
of naturally occurring cephalosporin C (Sudo et al., 2014). First-generation cephalosporins include 
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cephalothin, cefazolin, cephapirin, cephradine, cephalexin, and cefadroxil. They have effective 
coverage of most Gram-positive cocci, such as streptococci and staphylococci. In contrast, they 
have limited coverage of Gram-negative bacteria such as Neisseria meningitidis, Haemophilus. 
influenza. Klebsiella pneumoniae, Escherichia. coli, and Proteus mirabilis are Gram-negative 
bacteria that remain more sensitive to first-generation cephalosporins. Cephalosporins of the 
second generation possess less activity toward Gram-positive cocci compared with first generation 
cephalosporins but have enhanced activity against Gram-negative bacteria. Cefuroxime and 
cefprozil are members of second generation cephalosporins with antibacterial activity able to 
withstand the Temoneira (TEM-1) β-lactamase  occurring on transmissible plasmids in N. 
gonorrhoeae and H. influenzae, in addition to the ampicillin cephalosporinase (AmpC) for the 
latter as well as sulfhydryl-variable (SHV-1). (Sekyere, Govinden and Essack, 2016). Third 
generation cephalosporins have additional coverage of Gram-negative bacteria and are frequently 
used to treat infections caused by bacteria resistance to first- and second-generation cephalosporins 
or different β-lactam resistant infections caused by drug-resistant N. meningitidis, H. influenza, or 
Streptococcus pneumonia, and more importantly, Pseudomonas aeruginosa. Ceftriaxone, 
cefotaxime, ceftazidime, cefpodoxime, cefdinir, and cefixime belong to the third generation. In 
general, the ability to withstand hydrolysis by β-lactamases increases as we move from the first 
generation to the fifth. Third generation cephalosporins confer added stability to β-lactamases than 
first or second generations, particularly those produced by Klebsiella. spp, E. coli, and 
Haemophilus influenza. Fourth generation cephalosporins include cefepime and cefpirome which 
have the same spectrum of activity as the third generation in addition to much more noteworthy 
coverage of β-lactamase-producing Gram-negative bacteria. Cephalosporins of the fifth generation 
include ceftaroline. It differs from the rest of the cephalosporins by its indication for methicillin-
resistant Staphylococcus aureus (MRSA). While Enterococcus faecalis and Listeria 
monocytogenes are also covered with ceftaroline, it does not embrace Pseudomonas aeruginosa 
(Bui and Preuss, 2020). 
1.2.3.3 Cephamycins 
Cephamycins were regarded as a possible answer to the emerging threat of bacteria resistant to 
cephalosporins. The pharmacology of this class of compounds, derived from a bacterial natural 
product, cephamycin C, is similar to that of cephalosporins, and these compounds (including 
cefoxitin, moxalactam, and cefotetan) are also known as second-generation cephalosporins. The 
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characteristic 7-methoxy side chain in the cephamycin cefoxitin gives stability against β-
lactamases of TEM type, including ESBLs. It has beneficial antibacterial activity against 
methicillin-susceptible Staphylococcus aureus (MSSA) and also enteric bacteria, that do not 
contain high levels of AmpC (Bush and Bradford, 2016). With an antimicrobial activity 
comparable to that of cephalosporins of the 3rd and 4th generation, the novel oxacephem 
moxalactam, or latamoxef, has excellent hydrolysis stability against β-lactamases (Bush and 
Bradford, 2016). 
1.2.3.4 Carbapenems 
In the 1980s, a new β-lactam group of antibiotics stable to hydrolysis by all β-lactamases including 
ESBLs was introduced. They are bactericidal antibiotics with proven effectiveness against bacteria 
producing ESBLs (Hawkey and Livermore, 2012). Carbapenems are noteworthy for their stability, 
except for the evolving carbapenemases mainly found in Gram-negative bacteria (Kiratisin et al., 
2012). The mechanism of action of carbapenems occurs after penetration into the bacterial cell 
wall and attachment to particular PBPs that include 1a, 1b, 2, and 3 that leads to the killing of 
bacteria. Current knowledge describes the inhibition of transpeptidase as the predominant target 
enzyme of carbapenem. A covalent bond is established through transpeptidation by PBPs, 
specifically the carboxypeptidase and transpeptidase enzymes that inhibit their peptide cross-
linking actions during the biosynthesis of peptidoglycan resulting in cell death by autolytic action 
(Codjoe and Donkor, 2018). There is a lot of focus on the substantial nature of the glycan 
backbone. When PBPs are repressed, the strength of the cell wall is compromised, and because of 
autolysis, the glycan backbone fails and, ultimately, osmotic pressure in Gram-negative bacteria 
destroys the cell (Papp-Wallace et al., 2011). 
Several examples, including meropenem, imipenem, doripenem, panipenem, ertapenem, and 
biapenem, are used worldwide due to the growing resistance of the Enterobacterales to 
cephalosporine antibiotics (Patel and Bonomo, 2013). However, in general, due to their 
concentration-independent killing effect for bacteria, carbapenems are prioritized to treat 
infectious or life-threatening infections over other types of antibiotics (Watkins and Bonomo, 
2013). 
Imipenem was used as the first therapeutic agent for non-carbapenemase-producing enteric 
bacteria after failure of chemically unstable thienamycin. Its spectrum of activity covers non-
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fermentative and anaerobic Gram-positive and Gram-negative bacteria. Thereafter, more agents 
such as meropenem, ertapenem, and doripenem, were developed which vary slightly in their 
antibacterial activity, i.e., meropenem and doripenem have higher activity compared to imipenem 
against Enterobacterales and P. aeruginosa. Biapenem and tebipenem are two carbapenems 
licensed for Japan with the same range of activity as earlier ones, in addition to providing greater 
hydrolytic stability compared to imipenem or meropenem for MBLs (see section 1.2.5.1.2) (Bush 
and Bradford, 2016).  
Comparatively, doripenem is reasonably stable against hydrolysis by most β-lactamases among 
the carbapenems. Evidence has shown that doripenem also is less sensitive and much slower in 
carbapenemase hydrolysis (from 2 to 150 fold) than imipenem (Chahine, Ferrill and Poulakos, 
2010; Queenan et al., 2010). Ertapenem, meropenem, and imipenem are poorly orally absorbed, 
and require parenteral administration (Watkins and Bonomo, 2013). 
Imipenem, doripenem, and meropenem have an in vivo half-life of almost one hour, whereas 
ertapenem has an estimated half-life of four hours, making it suitable for once-daily administration. 
Imipenem is known, in contrast to the other carbapenems, for its dose-dependent gastrointestinal 
side-effects. Many carbapenems are degraded via the dehydropeptidase-1 (DHP-1) enzyme found 
within the renal tubules and need co-administration with a DHP-1 inhibitor like cilastatin. The 
latter types of carbapenems, including doripenem and ertapenem, require no DHP-1 inhibitor since 
they are more stable. These compounds differ in their linking to PBP, thereby providing distinct 
behaviour variations against different bacterial species (Codjoe and Donkor, 2018). For example, 
a study evaluated the selectivity of 22 commercially available β-lactams for PBPs in live E. coli 
DC2. E. coli possesses three class A (PBP1a, PBP1b, and 26 PBP1c) and two class B (PBP2 and 
PBP3) high molecular weight PBPs, also has seven low molecular weight (class C) (PBP4, PBP5, 
PBP6, PBP6b, PBP7, PBP4b, and AmpH). Meropenem among these β-lactams inhibited PBP2 
and PBP4. PBP2, PBP4, PBP7, and PBP8 were inhibited by doripenem and faropenem and are 
therefore identified as not selective (Kocaoglu and Carlson, 2015). 
1.2.3.5 Monocyclic β-lactams 
.These are β-lactams containing a monobactam nucleus with substitution in their monocyclic ring, 
i.e. sulfonic acid substituent (aztreonam) and group substitution of O-sulfates (BAL30072, novel 
monosulfactam), with the former being the only one authorized to be used clinically in 2016 (Bush 
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and Bradford, 2016). They are resistant to β-lactamases and effective against Gram-negative rods, 
though not on bacteria or anaerobes that are Gram-positive (Fernandes, Amador and Prudêncio, 
2013). Aztreonam was effectively used for multidrug-resistant β-lactamase-producing species 
before the advent of serine carbapenemase and ESBLs, but BAL30072 demonstrated synergistic 
activity in combination with β-lactamase inhibitors and greater stability to serine carbapenemase 
against hydrolysis compared to aztreonam (Mushtaq et al., 2013; Bush and Bradford, 2016).  
Strains expressing MBLs confer resistance to all β-lactam antibiotics in Gram-negative bacteria, 
except for monobactams, which are inherently stable against MBLs. However, established first-
generation monobactam drugs such as aztreonam have limited clinical effectiveness against strains 
that express MBL because they are frequently co-expressed with other serine β-lactamases in 
clinical isolates. Studies had been carried out to optimize novel monobactams by increasing their 
stability to serine β-lactamases, while preserving intrinsic stability against MBL. This led to the 
discovery of LYS2288 (compound31). In the presence of all classes of β-lactamases, LYS228 is 
potent and displays potent activity against CRE (Reck et al., 2018). 
1.2.3.6 β-lactam/β-lactamase inhibitor combinations 
Clavulanic acid was the first β-lactamase inhibitor identified in 1972, followed by sulbactam in 
1978 and tazobactam in 1984, named the classical β-lactamase inhibitors (Toussaint and 
Gallagher, 2015). Clavulanic acid has a novel clavam structure and is an inhibitor for 
staphylococcal penicillinases and most of the plasmid-encoded penicillinases present in 
Enterobacterales. Clavulanic acid’s inhibition spectrum spans most class A β-lactamases, 
including ESBLs and, to a lower extent, serine carbapenemases. It firstly acylates the β-lactamase 
active site serine with temporary inhibition that includes hydrolysis of clavulanic acid before the 
enzyme completes the inactivation. Clavulanic acid acts against β-lactamase-producing enteric 
bacteria synergistically with penicillins and cephalosporins to inhibit particular β-lactamases, 
enabling the β-lactam counterpart to kill the bacteria. A variety of penicillanic acid sulfones are 
synthesized by medicinal chemists with a similar activity spectrum and perform the same general 
inhibitory/inactivation mechanism as clavulanic acids, such as sulbactam and tazobactam. In 
general, none of the inhibitors have substantial antibacterial efficacy in monotherapy, although 
there are several notable exceptions (Bush and Bradford, 2016). Sulbactam shows less activity 
against β-lactamases of class A than clavulanic acid or tazobactam; however, it is more active 
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against β-lactamases of class C and demonstrates antimicrobial activity against A. baumannii. 
Tazobactam shows better activity than the others against cefotaximase-München (CTX-M) type 
enzymes (class A group) and can inhibit particular Class C and D β-lactamases (insignificantly) 
(Toussaint and Gallagher, 2015). 
None of these inhibitors are effective in inhibiting MBLs and their limited activity toward serine 
carbapenemases does not translate into clinical susceptibility due to the carriage of multiple β-
lactamases in the bearing organisms (Bush, 2015). Even with the substantial inhibitory activity 
observed in clavulanic acid and tazobactam action against single ESBLs, it is not sufficient to 
protect large amounts of their accompanying penicillins and/or co-expression of many β-
lactamases (Jones-Dias et al., 2014). 
The advent of inhibitor-resistant bacterial strains and inadequate inhibitory action of conventional 
β-lactam inhibitors against carbapenemases resulted in the development of the ‘second generation’ 
of β-lactamase inhibitors (BLIs) that include avibactam, vaborbactam, relebactam, zidebactam, 
and nacubactam as highly active inhibitors of Ambler class A and C β-lactamases (Docquier and 
Mangani, 2018). 
A new class of non-β-lactam β-lactamase inhibitors has developed, based on a novel joined 
diazabicyclo-octane (DABCO) structure. One of the first inhibitors, avibactam, has a wider 
spectrum of activity covering class C cephalosporinases, and some class D oxacillinases (Ehmann 
et al., 2013). Avibactam has a unique inhibition mechanism; this does not have a β-lactam core but 
retains the potential to target β-lactamase carbamylateits covalently through the opening of the 
avibactam ring. In contrast to ‘older’ βlactamase inhibitors, the reaction is reversible, with 
deacylation leading to regeneration of the preserved avibactam capable of rebinding rather than 
hydrolysing (Ehmann et al., 2012). This mechanistic distinction from the older inhibitors helps 
make avibactam particularly effective in protecting the β-lactam companion against hydrolysis by 
chromosomal and plasmid-mediated β-lactamases (Lahiri et al., 2014). Avibactam has been 
combined with ceftazidime for therapeutic use and is being developed in combination with 
ceftaroline or aztreonam (Livermore et al., 2015). Other DABCOs involve RG6080 and relebactam 
in combination with imipenem. Both exhibit a comparable spectrum of activity to avibactam, 




Zidebactam combination with cefepime for the prevention of Gram-negative infections 
demonstrated potent activities against Entrobacterales and P. aeruginosa producing β-lactamases 
of clinical significance (Sader et al., 2017). Enmetazobactam (formally AAI101) is a penicillanic 
acid sulfone identified as an ESBL inhibitor with action against selected enzymes of class C and 
class D carbapenemases, and also some class A carbapenemases produced by Enterobacterales 
(Tselepis et al., 2020). The combination of cefepime/enmetazobactam yielded better results than 
recently approved combinations, including ceftazidime/avibactam, ceftolozane/tazobactam, and 
imipenem/relebactam against MDR ESBLs-producing Enterobacterales strains (Morrissey et al., 
2019). Nacubactam, also has demonstrated efficacy against class A and class C β-lactamases in 
combination with meropenem, and improved antibacterial killing of ceftazidime-avibactam-
resistant isolates has been observed in vitro (Monogue et al., 2018). 
New structures mainly oriented towards impairing MBLs have been discovered in the last few 
years, with the compound ANT2681 (Antabio) possibly being one of the most important examples. 
This novel thiazole-carboxylate inhibitor is the product of a pyridine-2-carboxylic acid hit-to-lead 
program in medicinal chemistry and is a preclinical candidate with clinical potential for 
development as a particular inhibitor of MBLs (Davies et al., 2020). By interaction with the 
dinuclear zinc ion cluster present in the active site of these enzymes, ANT2681 inhibits the activity 
of MBLs (Everett et al., 2018). The inhibitor shows high NDM-1 affinity, lower VIM-1 affinity, 
and very slight IMP-1 affinity. It has shown effectiveness in a mouse thigh model with an NDM-
1-producing clinical isolate of K. pneumoniae. ANT2681 is therefore undergoing preclinical 
development to combine it with meropenem as a potential therapy for MBL-producing CRE-
induced serious infections (Vázquez-Ucha et al., 2020). 
The boronic acid inhibitor RPX70099 is another novel class of synthetic non-β-lactam β-lactamase 
inhibitors (vaborbactam). This is developed in combination with meropenem against serine-based 
carbapenemase-producing pathogens, and has been known to be an effective serine β-lactamase 
inhibitors for several years (Lapuebla et al., 2015). This combination was approved because of its 
potent activity against Ambler class A carbapenemases, such as KPC, by the Food and Drug 
Administration (FDA) in October 2017 (Ackley et al., 2020). 
In acknowledging the need for viable solutions to the small new antibiotic pipeline, the Infectious 
Diseases Society of America (IDSA) initiated the '10×'20 campaign' in 2010, aiming for the 
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production and regulatory approval of 10 novel, effective and safe systemically administered 
antibiotics by 2020 (Boucher et al., 2013). There was significant interest in combinations of β-
lactam/β-lactamase inhibitors, promising in vitro action against MDR, XDR, and even PDR Gram-
negative bacteria, as novel agents to counter β-lactam antibiotic resistance (Magiorakos et al., 
2012). Over the last decade, the FDA has licensed six β-lactam containing agents: ceftaroline, 
ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-
relebactam and cefiderocol. four of which are β-lactam antibiotics paired with β-lactamase-
inhibitors (Bush and Bradford, 2019). 
1.2.4 β-Lactam resistance mechanisms 
It is acknowledged that β-lactams remain both the most prescribed class of antibiotics and the most 
significant in terms of sales confirming their continuing central role in bacterial infection 
management (Klein et al., 2018). The efficacy of β-lactam antibiotics depends on the accessibility 
of its targets, their susceptibility to β-lactamases enzymatic inactivation, and the ability of β-lactam 
to suppress target PBPs. Changing one or a combination of these parameters can contribute to 
resistance (Kong, Schneper and Mathee, 2010), and like any other antibacterial drug used within 
the clinical setting, their use is sooner or later accompanied by the development of resistant strains, 
which can spread quickly on a global scale after the acquisition of resistance determinants (Khan, 
Maryam and Zarrilli, 2017). β-lactam resistance may be intrinsically expressed by chromosomal 
genes or acquired through plasmids. Plasmid-mediated resistance due to HGT is a more worrisome 
form of resistance because of the ease of spread. Multiple resistance mechanisms to β-lactams, 
including target modification, efflux pumps, and hydrolysing β-lactamases enzymes, have been 
identified (Docquier and Mangani, 2018). 
The biggest single cause of resistance to β-lactam antibiotics is antibiotic-inactivating enzymes, 
the β-lactamases, that are versatile enzymes present in a number of bacterial species with a 
restricted range of molecular structures. A commonality is the ability to hydrolyse β-lactam ring-
containing chemical compounds (Kong, Schneper and Mathee, 2010; Bush, 2018). β-lactamases 
often contain a reactive serine residue at their active site (serine β-lactamases) or at least one 
divalent zinc atom (MBLs) that acts catalytically. Serine β-lactamases are varied in structure and 
hydrolytic pattern; however, all of these enzymes hydrolyse β-lactams at their catalytic site in a 
multi-step reaction via a serine residue (Bush and Bradford, 2019). 
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Decreased permeability of the lipopolysaccharide structure of the Gram-negative bacterial cell 
wall, and alteration or loss of trans-membranous hydrophilic protein channels, the porins, function 
as another resistance mechanism that hinders β-lactams from accessing their PBP targets. This 
mechanism only results in minimal resistance but may function synergistically with the expression 
of β-lactamases or active efflux to impose high resistance levels. Efflux systems consist of 
cytoplasmic membrane proteins which use the proton-motive force to extrude drugs. Also, bacteria 
seek to alter PBP-target affinity for β-lactam antibiotics, acquire resistant PBPs or increase PBP-
target amounts in the absence of β-lactamases as other mechanisms of resistance (Fisher and 
Mobashery, 2016; Bush, 2018). 
The production and proliferation of inactivating enzymes were identified early after the antibiotic 
class β-lactam was discovered and clinically administered. The β-lactam-hydrolysing enzymes 
have increased their spectrum of activity over time, starting with penicillinases, followed by 
cephalosporinases, then to ESBLs, and more recently MBLs and other carbapenemases. The MBLs 
also had a significant effect on the efficacy of carbapenems used to treat multi-resistant Gram-
negative bacilli (Garcia, 2013). 
Two main physiologically important enzyme properties, i.e., structure and function, are the basis 
of the nomenclature for β-lactamases. In 1980, Ambler first described structural classes that used 
four amino acid β-lactamase sequences to define class A enzymes including serine at the active 
site and class B MBLs. Since then, based upon the molecular size and unique homologous motifs, 
class C and class D serine-based β-lactamases have been identified (Bush and Bradford, 2020). 
Philippon et al., have recently proposed modifications to the Ambler’s class A on the basis for a 
structure-based and phylogenetic classification. Two subclasses (A1, A2), six major clusters (e.g., 
wider spectrum β-lactamases (WSBL), naturally limited spectrum β-lactamases (LSBL), and 
several additional clusters were defined based on conserved (>90%) and unique patterns. Residues 
such as V231GDKTG and S70TFKAL were recognized for subclass A1, V231AHKTG and 
S70VFKFH for subclass A2 (Philippon et al., 2019). 
Functional classification schemes have been established for over 50 years based on biochemical 
properties, such as substrate compositions, relative hydrolysis rates compared to the conventional 
β-lactams, and interactions with inhibitors. Bush et al., suggested revised functional classification 
based on a combination of biochemical properties and structural class assignments in 1995, with 
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Bush and Jacoby adding additional subgroups in 2010. To identify β-lactamases that include more 
than a single group or class, other functional names are frequently used. For instance, 
carbapenemases, β-lactamases efficient in hydrolysing carbapenems at a clinically significant rate, 
may correlate to structural class A, B, or D, or may relate to functional group 2df or 2f, or to group 
3. ESBLs may contain Class A, C or D enzymes or may be classified as groups 1e, 2be, 2de, and 
2e (Bush and Bradford, 2020). 
Ambler class A serine β-lactamases are the largest number of enzymes with a comprehensive 
activity spectrum. Penicillinases related also to functional group 2b, are broad-spectrum enzymes, 
as they hydrolysed the first approved for medicinal use penicillins and cephalosporins. In this 
group also belong two frequently occurring β-lactamases identified in Enterobacterales designated 
as TEM-1 and SHV-1 most often conferring resistance in E. coli and K. pneumoniae, respectively 
(Beceiro et al., 2011). Other enzymes belong to the same group, and 2be subgroup are ESBLs. The 
first evolving ESBLs were derivatives of TEM and SHV that had amino acid substitutions resulting 
in an 'expanded' profile of the substrates, and they hydrolyse penicillins and cephalosporins that 
are both narrow and broad in their microbiological spectrum. For the first decade of ESBL 
discovery, they were ubiquitous, but in recent years, due to the worldwide spread of CTX-M-
producing isolates, their importance has diminished (Bush and Bradford, 2019). CTX-M-type 
enzymes which are normally produced by Enterobacterales species including Shigella spp., 
Salmonella spp., C. freundii, S. marcescens, and Enterobacter spp. as well as some non-
fermentative bacteria (Cantón, González-Alba and Galán, 2012) are commonly inhibited by 
tazobactam, newer BLIs, including avibactam, relebactam, vaborbactam, and by clavulanate and 
sulbactam to varying degrees (Lomovskaya et al., 2017). Other variants of TEM and SHV, called 
inhibitor-resistance β-lactamases (functional group 2br), are not inhibited by clavulanic acid and 
sulbactam, however, most of them remain sensitive to inhibition by tazobactam and avibactam 
(Lahiri et al., 2016). 
Serine carbapenemases belong to Ambler class A enzymes and are capable of hydrolysing 
carbapenems (serine carbapenemases) while MBLs distinguished by the presence of Zn2+ at the 
active site are members of Ambler class B and are classified in functional group Bush–Jacoby– 
Medeiros 2f, and group 3 respectively. These will be discussed in section (1.2.5.1). 
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AmpC β-lactamases belong to Ambler class C, functional group 1. These contribute resistance to 
most cephalosporins, including broad-spectrum cephalosporins such as ceftazidime, cefotaxime, 
and ceftriaxone, and cephamycins such as cefoxitin. They also hydrolyse penicillins and other 
monobactams to a lesser scale (Bush and Jacoby, 2010). The basal expression of chromosomal 
AmpC-type β-lactamases is usually small, but increased expression levels can be produced after 
exposure to certain β-lactams, which are especially important in clinical isolates of E. cloacae, C. 
freundii, E. aerogenes, S. marcescens and P. aeruginosa. AmpC β-lactamases may also be 
plasmid-mediated are disseminated widely. Many of these variants are CMY-1, originating from 
C. freundii, MIR and ACT families of Enterobacter spp., and DHA family, of Morganella 
morganii (Bush and Jacoby, 2010). When analysing the induction of β-lactamase in bacterial cells, 
the most important factors are the differentiation of chromosomal-encoded β-lactamases into 
constitutive and inducible. In both conditions, the former is present at a consistent level, while the 
latter is suppressed in the absence of antibiotics and triggered in the presence of β-lactam agents 
(Kong, Schneper and Mathee, 2010). Last in this classification, are oxacillin-hydrolysing β-
lactamases (OXA-type) grouped as functional group 2d β-lactamases of molecular class D. OXA 
enzymes are often more hydrolytic to oxacillin than penicillin G, and some members of this group 
can hydrolyse cephalosporins or carbapenems. There are many OXA β-lactamases associated with 
an ESBL phenotype, such as OXA-11, OXA-14, and OXA-20 (Evans and Amyes, 2014). 
However, they are inhibited only slightly by clavulanate, while others are inhibited by tazobactam 
and avibactam (Ehmann et al., 2013). 
The clinical effect of β-lactams is threatening by mobile β-lactamases in Gram-negative bacteria 
include ESBLs and serine and metallo-carbapenemases. β-lactamase-encoding genes can be 
acquired horizontally via plasmids, transposons, gene cassettes, integrons, and insertion 
sequences, with few species barriers for their transmission (Bush, 2018). 
1.2.5 Carbapenem resistance mechanisms 
Among the β-lactams, carbapenems are the most effective against Gram-positive and Gram-
negative bacteria, offering a broad spectrum of antibacterial activity. A particular molecular 
structure, along with the β-lactam ring, gives added stability against most β-lactamases, including 
ESBLs. Consequently, carbapenems are established as one of the most effective drugs for 
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managing bacterial infections, and the advent and spread of resistance to these antibiotics is a 
significant public health issue (Nordmann, Naas and Poirel, 2011; Meletis, 2016). 
Carbapenems are often referred to as "last-resort antibiotics" or "last-line agents" when infected 
patients become critically ill or are suspected of harbouring resistant bacteria. The extensive use 
of carbapenems for empirical and direct treatment of serious infections has led to the development 
of carbapenem hydrolysing β-lactamases, also known as carbapenemases, as the most recognized 
mechanism of carbapenem resistance (Papp-Wallace et al., 2011; Ramsamy et al., 2020). 
Carbapenem resistance may also result from altered PBPs, or reduced cell entrance due to 
upregulated efflux pumps or modifications through the outer membrane proteins (OMPs) together 
with ESBL and AmpC β-lactamase production (Bush and Bradford, 2020). 
Infections generated from extensively drug-resistant (XDR) Gram-negative bacteria have emerged 
as one of the serious threats in the world, not least of which are the globally rising carbapenem-
resistant bacteria (Prestinaci, Pezzotti and Pantosti, 2015; Logan and Weinstein, 2017; Bonomo et 
al., 2018). Resulting in limited treatment choices and an unavoidably high mortality rate, they are 
becoming a major global concern (Poirel et al., 2011; Cui, Zhang and Du, 2019; Fasciana et al., 
2019). 
Enterobacterales is a large group of rod-shaped, Gram-negative bacilli bacteria. They were by far 
the most isolated bacteria from clinical samples and accounted for up to 80% of all clinically 
relevant Gram-negative bacilli isolates in 2016, and up to 50% of all clinically significant bacteria. 
Enterobacterales cause nosocomial and community-acquired diseases, and progressively became 
MDR (Perovic et al., 2016). Due to this, WHO compiled a list of antibiotic-resistant bacteria for 
which new antibiotics urgently need to be developed in 2017. Based on the urgency in which new 
antibiotics are needed, this list is categorized into three categories: critical, high, or medium 
priority. Within the critical priority category are Enterobacterales resistant to carbapenems and 3rd 
generation cephalosporins (Tacconelli et al., 2018). 
Enzyme-mediated carbapenem resistance is attributable to carbapenemases capable of inactivating 
carbapenems along with other β-lactam antibiotics. This remains the most frequent resistance 
mechanism within CREs. Carbapenemase-producing Enterobacterales (CPE) is CRE, which are 
carbapenem-resistant due to the production of carbapenemases. This form of resistance is the most 
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important clinically since these enzymes hydrolyse all or nearly all of the β-lactams, resulting in 
high minimum inhibitory carbapenem concentrations (MICs), are encoded by genes that are 
horizontally transferable by plasmids or transposons, and are usually associated with genes 
encoding other determinants of resistance (Meletis, 2016). 
Initially, the carbapenemases were mediated chromosomally within few species. However, they 
are plasmid-mediated and sometimes chromosomally- and plasmid-mediated, resulting in 
horizontal transmission between different bacterial species and genera. The capacity of different 
MGEs to develop, harbour, and disseminate various resistance genes leads to resistant species 
being effectively and actively spread (Singh-Moodley and Perovic, 2016). 
1.2.5.1 Carbapenemases 
1.2.5.1.1 Class A Carbapenemases  
Class A β-lactamases include the carbapenemase genes encoded by chromosomes such as the 
imipenem-hydrolysing β-lactamase-1(IMI-1), Serratia marcescens enzyme (SME), not metallo-
enzyme carbapenemase A (NMC-A), Serratia fonticola carbapenemase-1(SFC-1), and those 
encoded by plasmids such as the variants of IMI (IMI-1 to IMI-3), Klebsiella pneumoniae 
carbapenemases (KPC-2 to KPC-13), and derivatives of Guiana extended spectrum (GES-1 to 
GES-20) (Nordmann and Poirel, 2014; Naas, Dortet and Iorga, 2016; Bonomo, 2017). Serine-
based carbapenemases can hydrolyse all β-lactams including aztreonam but are inhibited by 
clavulanic acid, sulbactam, avibactam and tazobactam BLIs, as well as by derivatives of boronic 
acid (Sekyere, Govinden and Essack, 2016; Codjoe and Donkor, 2018). Among these, the KPCs 
are the most widespread, having spread across the globe and induced outbreaks in several North 
American, Asian, and European countries and in Africa within a few years of its detection. KPC 
producers are multidrug-resistant thereby reducing the therapeutic options for KPC-related 
infections (Kazmierczak et al., 2016; Codjoe and Donkor, 2018). Recently, at least 79 variants of 
KPC enzymes have been identified from various pathogens, 40 of which differ from the initial 
KPC-2 and KPC-3 enzymes by fewer than five amino acids 
(https://www.ncbi.nlm.nih.gov/pathogens/refgene/#KPC). KPC was first described from an 
isolate of K. pneumoniae from a single patient in North Carolina, United States, in 1996. Although 
the next steps in propagation were not known, in the following decade, K. pneumoniae expressing 
KPC-2 becoming endemic in New York City (Bush and Bradford, 2020). KPC-producing 
pathogens have subsequently spread well, exceeding the northeast of the United States, so that 
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KPC enzymes have become reported globally (Castanheira et al., 2017). KPCs are not inhibited 
by clavulanate or tazobactam, but are significantly inhibited by avibactam, relebactam, and 
vaborbactam (Kazmierczak et al., 2016; Lomovskaya et al., 2017; Hackel et al., 2018; Carpenter 
et al., 2019). 
GES enzymes were originally identified as ESBLs, but a single-point mutation extended the 
spectrum of these enzymes, adding carbapenem-hydrolysing activity to GES-2, GES-4, GES-11 
and GES-14 (Nordmann and Poirel, 2014). NMC-A and IMI enzymes are chromosomally coded 
carbapenem-hydrolysing β-lactamases present in E. cloacae. Similarly, SME is a chromosomal 
enzyme originating primarily from S. marcescens shows the highest amino acid sequence 
similarity (70%) to NMC-A. SME enzymes develop resistance to carbapenems, but have minimal 
hydrolytic activity against extended-spectrum cephalosporins (Bush and Bradford, 2019). 
Compared to a zinc metal in MBLs, this class harbours the serine amino acid at its active site, thus 
being called serine carbapenemases. Therefore boronic acid derivatives are inhibitors used to 
detect such enzymes in CPE (Sekyere, Govinden and Essack, 2015; Sekyere, Govinden and 
Essack, 2016). 
1.2.5.1.2 Class B Metallo-β-lactamases (MBLs) 
Class B metallo-β-lactamases comprise of NDM-1 (New-Delhi metallo-β-lactamase-1), VIM 
(Verona integron-encoded metallo-β-lactamase), IMP (Imipenem-resistant Pseudomonas type 
carbapenemases), SIM (Seoul imipenemase) and GIM (German imipenemase). MBLs hydrolyse 
most β-lactams, including carbapenems, but monobactams are not hydrolysed. Chelating agents 
such as ethylene diamine tetra acetic acid EDTA can inhibit them, but they are not inhibited by 
inhibitors in the latest FDA-approved BLI combinations. Plasmid-encoded MBLs pose a major 
clinical threat as they are embedded inside mobile genetic structures that can distribute and harbour 
genes of resistance to other classes of antimicrobials (Bush and Bradford, 2019). However, within 
acquired variants of MBLs, IMP, VIM, and NDM are the most common and have now been 
distributed throughout the world (Kazmierczak et al., 2016). At their active site, they incorporate 
one / two zinc atoms, hence the term MBLs. The addition of a chelating agent, such as EDTA to 
the enzyme solution, impedes the enzyme as the chelator absorbs all the zinc atoms, rendering it 
difficult for the enzyme to work (Sekyere, Govinden and Essack, 2016). 
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MBLs were described in various Gram-negative clinical isolates, including many species of 
Enterobacterales, P. aeruginosa and Acinetobacter spp. IMP enzymes were first to be identified 
as acquired MBLs. Enzymes of the type VIM have become widespread and are especially 
prevalent in the Mediterranean region (Bush and Bradford, 2019). Based on variations in their 
primary zinc coordination shell and their amino acid sequence, MBLs are divided into three 
subclasses: B1, B2, and B3. Sequence identity varies from 14 to 24% between subclass B1 and B2 
enzymes, while sequence identity varies from 2% to 14 % between subclass B3 and subclasses B1 
and B2 (Karsisiotis, Damblon and Roberts, 2014). These structural differences in established and 
emerging MBLs presents a challenge to the development of effective MBL inhibitors (Somboro 
et al., 2019). The NDM-1 gene may well have been acquired from the population by mid-2010 and 
transmitted by tourists traveling worldwide to other countries such as Europe and the United States, 
while NDM-1 was also identified in environmental samples of the same strains. Up to 89 and 73 
varieties of carbapenemases of the type IMP and VIM have been identified recently 
(https://www.ncbi.nlm.nih.gov/pathogens/refgene/#IMP;https://www.ncbi.nlm.nih.gov/pathogen
s/refgene/#VIM). The VIM and IMP families have certain overlap with regard to which plasmids 
they are borne on and that they are aligned with certain integrons (Codjoe and Donkor, 2018). The 
amino acid sequence similarity range of the VIM family is up to 10%, about 15% for IMP, and 
70% among the two families. Both hydrolyse all β-lactams, but for monobactams (Marsik and 
Nambiar, 2011). 
Less frequently acquired MBLs tend to be constrained to certain geographic areas or have only 
been identified in a few instances, including Sao-Paolo metallo-β-lactamase (SPM) and German 
imipenemase (GIM), found in Brazilian P. aeruginosa isolates (Sao Paulo) and Germany, 
respectively (Wendel et al., 2013). 
1.2.5.1.3 Class D OXA-48-Type carbapenemases 
Some other serine-based carbapenemases belong to class D, mostly the OXA-48-type. These are 
called oxacillinases because of their preferred oxacillin hydrolysis instead of penicillin. They are 
now considered a broad group of enzymes displaying variability in their substrate profiles and 
sequences. OXA carbapenemases are therefore distinguishable from other molecular classes where 
amino acids sequences of  class D and class A or class C β-lactamases share less than 20% 
similarity (Poirel, Potron and Nordmann, 2012).This class of enzymes is not inhibited by EDTA 
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but is affected variably by the β-lactamase inhibitors tazobactam, sulbactam and clavulanic acid 
(Sekyere, Govinden and Essack, 2015). Within the Class D OXA family of β-lactamases, only a 
small number have functional roles as carbapenemases. OXA-23, OXA-40, and the frequently 
prevalent OXA-48, with their related versions, OXA-181, OXA-162, and OXA-232, are among 
these (Mairi et al., 2018). They usually have hydrolytic activity toward penicillins and 
carbapenems and slightly inhibited by β-lactamase inhibitors, with the exception of avibactam 
(Haidar et al., 2017; Lomovskaya et al., 2017). 
Class D carbapenemases are reported to have high temocillin resistance that is used in their 
identification in enterobacterial hosts (Sekyere, Govinden and Essack, 2016; Codjoe and Donkor, 
2018). The main concern regarding OXA carbapenemases is their capability to mutate and increase 
their activity spectrum quickly. Reports by Mathers et al. (2013) reported widespread identification 
of Class D in the Enterobacterales species rendering this class of carbapenemases a global threat 
and a significant public health concern (Mathers et al., 2013). OXA-48 was first observed amidst 
Turkish clinical isolates of K. pneumoniae and afterward spread to Europe and the Mediterranean 
region but were less commonly detected in the Americas (Mairi et al., 2018). However, several 
outbreaks have recently been reported in several countries in South America, including Colombia, 
Brazil, and Argentina (Villacís et al., 2020). 
Similar enzymes such as OXA-162, OXA-163, OXA-181, and OXA-232 have been found in 
various species of Enterobacterales and have spread into Europe and the Mediterranean regions 
(Kazmierczak et al., 2018). 
Because of their point mutant analogs with ESBLs, OXA-48-type producers are one of the most 
challenging carbapenemase producers to predict and their prevalence rates are difficult to estimate 
accurately. Moreover, 102 distinct OXA sequences were identified by 2011, 9 of which are 
extended-spectrum β-lactamases and a minimum of 37 of which were classified as carbapenemases 
(Nordmann, Naas and Poirel, 2011). More recently, 943 variants were detected in different 
pathogens (https://www.ncbi.nlm.nih.gov/pathogens/refgene/#OXA). 
1.2.5.2 Other Resistance Mechanisms 
Multiple mechanisms of resistance can occur, including target alteration (mutation or expression 
of alternative PBPs), restriction of cellular uptake by downregulation of the porins needed for the 
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entry of carbapenems, over-expression of efflux pumps, and development of enzymes that change 
or degrade (Matlashewski et al., 2017). While carbapenem resistance is mostly mediated by β-
lactamases in Gram-negative bacteria, for both Gram-negative and Gram-positive bacteria, other 
resistance mechanisms may also occur. The most evident mechanism is the production of low-
affinity PBPs that require substantial inhibitory concentrations of carbapenem for bacterial killing 
(Bush and Bradford, 2020). 
The access of carbapenems into periplasmic space and their subsequent interactions with PBPs in 
the cell membrane, may be restricted by manipulating porin expression or alterations in the porin-
encoding gene, leading to either total loss or deficiencies in the corresponding porin. For instance, 
in K. pneumoniae, the altered expression of ompk35 and ompk36 induces a high degree of 
ertapenem resistance (Elshamy and Aboshanab, 2020). Mutations in OMPs in Enterobacterales, 
can involve changes in regulatory mechanisms affecting the expression of OMPs or result in non-
functional or deleted OMPs (Bush and Bradford, 2020). Also, the expression of non-
carbapenemase β-lactamases in conjunction with the loss of porins is an alternative mechanism of 
developing resistance to carbapenems. For instance, this mechanism was observed in clinical E. 
coli isolate harbouring β-lactamase plasmid-encoded AmpC (blaCMY-2) that increased 
meropenem minimum inhibitory concentrations. Two mutations were required, resulting first in 
the loss of expression of porin and then in increased expression of CMY-2 β-lactamase (van Boxtel 
et al., 2017). AmpC-type β-lactamases cannot degrade carbapenems or barely do but can bind to 
them covalently in the periplasm and prevent them from reaching their targets (Goessens et al., 
2013). Overproduction of ESBLs and AmpCs paired with decreased outer-membrane permeability 
and/or overexpression of the efflux pump can also confer resistance to carbapenems (Meletis, 
2016; Sekyere, Govinden and Essack, 2016). 
Ertapenem is most significantly affected by porin manipulation among the carbapenems, while 
isolates can remain sensitive to other carbapenems. The decreased sensitivity to ertapenem 
primarily depends on AmpC/ESBL and level of porin mutations (Codjoe and Donkor, 2018). 
Another mechanism which may lead to carbapenem resistance is the active expulsion of 
carbapenems after their entry into the periplasmic space. This is regulated by tripartite efflux 
systems consisting of a cytoplasmic membrane protein transporter, a periplasmic connective 
protein, and an outer membrane. The overexpression of efflux pumps that remove carbapenems, 
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mainly meropenem, result in resistance to carbapenems and confers a MDR phenotype since 
quinolones, β-lactams and aminoglycosides are also popular substrates for efflux pumps (Meletis, 
2016). As affinity is dependent on physiochemical properties (e.g., electric charge, aromatic, or 
hydrophobic properties) rather than chemical structures, efflux pumps are generally capable of 
identifying various substrates. This explains the existence of pumps conferring for MDR, which 
can eject many structurally unrelated antibiotics (Elshamy and Aboshanab, 2020). 
1.2.6 Epidemiology of carbapenemase-producing Enterobacterales (CPE) in South Africa 
The burden of antibiotic resistance among Enterobacterales globally is substantial, continuously 
evolving and a significant challenge to public health (Tängdén and Giske, 2015). Nosocomial 
infections caused by these bacteria are associated with prolonged hospitalization, combined with 
exceedingly high mortality rates, particularly in carbapenemase-producing K. pneumoniae CPKP 
(Tzouvelekis et al., 2014). 
The global distribution of CPE isolates includes African countries, with NDM-1 and OXA-48 
being the most common carbapenemases, reported in Nigeria, Algeria, Angola, Gabon, Mali and 
South Africa (Rubin et al., 2014). In August 2011, the first NDM was identified in South Africa 
and the first KPC was identified in Africa in E. cloacae and K. pneumoniae in South Africa in 
private hospitals, in Pretoria and Johannesburg respectively. Ironically, neither this first NDM-1 
nor the subsequent NDM-1 in K. pneumoniae was isolated from patient with a travel history within 
or around the Indian continent (as origin of NDM first detection), suggesting local evolution 
(Lowman et al., 2011; Brink et al., 2012). This indicates that the epidemiology of such enzymes 
in South Africa is more complicated than the reports of cases from several other countries. Thus, 
bacteria with NDM in South Africa may consist of local and imported cases of NDM-producing 
bacteria co-existing within the country. 
In addition, Brink and colleagues (2012) reported carbapenemases such as OXA-48 and its’ 
derivatives among hospitalized patients with infections associated with Enterobacterales in 
Johannesburg, Port Elizabeth and Cape Town after screening isolates from a private laboratory 
network in the country. Moreover, VIMs were detected in K. pneumoniae in Johannesburg and 
GES in Cape Town (K. pneumoniae), Witbank (E. cloacae), Bloemfontein (K. oxytoca) and Port 
Elizabeth (Serratia marcescens) (Brink et al., 2012). Several CPEs cases have been registered in 
the country since, with K. pneumonia, Citrobacter spp., Enterobacter spp. and E. coli implicated 
25 
 
as primary hosts. KPCs, NDM, OXA-types, IMP, GES and VIM were the major carbapenemases 
identified so far, while SMEs, GIM, SIM, NMCs and other carbapenemases were nominal with 
the vast majority reported from the regions of Gauteng and Western Cape (Sekyere, Govinden and 
Essack, 2016). 
A comprehensive analysis to raise awareness of South Africa's precarious state of public health 
was conducted in 2016, aiming to promote government action to implement policies that decrease 
resistance to reserve antibiotics (carbapenems, colistin, and tigecycline). Assessment of 
carbapenem resistance-reporting publications from early January 2000 and 20 May 2016 revealed 
that there were an estimated 2315 cases/infections resistant to carbapenem. Most of these recorded 
cases (n=1220) were from Gauteng province, followed by a smaller number from KwaZulu-Natal 
province (n = 515). The most common carbapenem-resistant isolates were the family members of 
Enterobacterales such as K. pneumoniae, E. cloacae, and S. marcescens. NDM (n=860) and OXA-
48 (n=584) were among the most reported carbapenemases intimating the potential endemicity of 
NDM and OXA-48 among Enterobacterales and other bacterial species in South Africa (Sekyere, 
2016). Perovic and colleagues also published similar findings in 2016 from private sector 
laboratories in South Africa, where a high prevalence of blaNDM-1 was observed in Gauteng 
province compared to blaOXA-48 through an evaluation of 9029 Gram-negative ESKAPE (E. 
faecium, E. faecalis, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, E. cloacae, and E. 
coli) isolates (Perovic et al., 2018). However, carbapenem resistance determinants may change as 
the same province reported an exponential increase in blaOXA-48–like producing K. pneumoniae 
strain where 471 K. pneumoniae isolates were positive for OXA-48–like enzymes among 1,247 
unique clinical isolates collected from a private laboratory network a year later (Lowe et al., 2019). 
Adopting advanced sequencing technologies allowed Pedersen and colleagues to investigate the 
molecular epidemiology of CRE clinical samples (n=45) collected by a private laboratory in 
Durban from patients hospitalized in 10 separate private hospitals between 2012 and 2013. 
Focusing on the carbapenem-resistance encoding determinants and their genetic support, they used 
WGS analyses to demonstrate complex patterns of dissemination of carbapenemase-encoding 
genes (blaNDM-1, blaGES-5, blaOXA-232, and blaNDM-5) via MGEs (e.g., integrons and 
insertion sequences) embedded in five different plasmids that appeared to mediate their horizontal 
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transfer, together with clonal transmission, between various species of Enterobacterales (Pedersen 
et al., 2018). 
Further research in the same province has also used WGS to study the genomic epidemiology of 
extensively drug-resistant K. pneumoniae isolates, focussing on determinants encoding 
carbapenem resistance, clonality, mobile genetic support, and epidemiological linkages. Between 
May 2016 and May 2017, rectal swabs were collected from patients admitted to the surgical, 
medical, and trauma ICU of a quaternary public hospital where a total of 263 patients were 
screened for CPE. In addition, K. pneumoniae clinical isolates involved in bloodstream infections 
were collected from the same wards during the same time. Five of the 263 rectal swabs were 
confirmed as carbapenem-resistant K. pneumoniae (CRKP), as were five blood culture samples 
collected from infected patients for comparison, and CPEs were collected from admitted patients. 
All isolates had the same capsular serotypes (KL149-wzc:928, wzi:110) and all except one 
(ST3136) belonged to the ST152 clone. Assessment of the genetic backbone of the carbapenemase 
as well as its flanking sequences placed blaNDM-1 to the multi-replicon plasmid that was 
identified in several other CRE isolates Comparative phylogenomic evaluation of the 10 CRKP 
isolates confirmed their similar epidemiological profiles (Ramsamy et al., 2020). 
1.2.7 The role of whole genome sequencing (WGS) 
The earliest application of WGS was the ability to assess resistance to antimicrobials from a single 
assay. WGS has the potential to generate data on any resistance gene or mutation present, and the 
data may then be evaluated to produce a genotypically inferred antibiotic resistance profile 
(antibiogram) or, possibly, to predict susceptibility (Ellington et al., 2017). 
Over existing gold-standard techniques that describe CRE, WGS is considered a powerful 
approach with significantly improved resolution capacity that provides extensive insights into 
strain-relatedness, molecular epidemiology, carbapenemase-containing plasmid replicon groups, 
prediction of factors affecting carbapenem resistance, point mutation, and the existence of other 
resistance mechanisms (Lynch et al., 2016). Moreover, it is now possible to describe the genetic 
environment surrounding these genes including MGEs such as integrons, insertion sequences (IS), 




WGS improves the ability to characterize and address CRE outbreaks, recognize, and anticipate 
epidemiological patterns, and develop new machine learning techniques to detect novel variants 
quickly (Taggar et al., 2020). 
Thus, scientists and public health professionals can now identify closely the spread, outbreak, 
infection epidemiology, and resistant bacteria using genomics and different bioinformatics tools 
(Kleinheinz, Joensen and Larsen, 2014). Large-scale and comparative analyses using these tools 
on human, animal, and environmental samples offered unparalleled insights into the global 
dissemination of antibiotic resistance genes and disseminating multidrug-resistant bacteria 
(Pesesky et al., 2015), resistance transmission networks (Pehrsson et al., 2016), and how diverse 
environments and phylogeny impact the evolutionary mechanisms of antibiotics resistance 
globally (Gibson, Forsberg and Dantas, 2015). As new algorithms for monitoring the spread of 
carbapenem-resistant bacteria in diverse fields, namely health care facilities and agricultural 
products, are being established, they are becoming more efficient and can to be interpreted with 
the degree of accuracy necessary to direct the improvement of infection control procedures and 
food safety protocols to limit the spread of infection (Lynch et al., 2016; Taggar et al., 2020). 
This study describes the molecular epidemiology of CPE infection and colonization in patients 
from ICU in a single public hospital in the KwaZulu-Natal area using WGS and bioinformatics 
analysis. Delineating the molecular signatures of CPEs will direct containment strategies to 
improve patient outcomes. 
1.3 Aim and objectives of the study 
1.3.1 Aim of the study 
The aim of the study was to delineate the molecular epidemiology of CPEs colonizing patients in 
ICU in a public hospital in the uMgungundlovu district. 
1.3.2 Objectives 
The objectives were to: 
1. Obtain rectal swabs from all consenting ICU patients on day 1, 3, 7 and weekly thereafter until 
death or discharge from the ICU. 
2. Screen the rectal swabs for CPE using Chrom-ID selective media. 
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3. Speciate and determine the antibiotic susceptibility profile of CPE using Vitek II according to 
EUCAST guidelines. 
4. Undertake ERIC-PCR to determine the clonality and relatedness of the CPE within the ICU. 
5. Undertake whole genome sequencing on representative isolates, and using bioinformatics tools 
delineate: 
• Antibiotic resistance genes. 
• Virulence genes. 
• Mobile genetic elements such as plasmids, transposons and integrons putatively associated 
with resistance and virulence. 
• MLST profiles. 
• Phylogeny of CPEs circulating in South Africa and beyond. 
1.4 Summary of methodology 
1.4.1 Ethical considerations 
This study has been ethically reviewed and approved by the UKZN Biomedical Research Ethics 
Committee (BREC) (Ref No BE709/18 and BREC/00001723/2020). Permission was sought to 
extend this study to include molecular biological investigations as described above. 
Permission was granted by the KwaZulu-Natal Department of Health, the uMgungundlovu District 
Manager, and the hospital Chief Executive Officer and ICU Manager. Voluntary informed consent 
was obtained from patients themselves, from their next of kin, or proxy consent from ICU manager. 
1.4.2 General methodology 
This was a descriptive sub-study on isolates collected from a larger PhD study, conducted in the 
public healthcare system at a general ICU, of a regional hospital that admitted both medical and 
surgical adult patients, to ascertain incidence and transmission of CPEs among this category of 
patients from February 2020 and March 2020. This study's population were all consenting adult 
patients admitted over one month. The researcher obtained rectal swabs from patients on day 1, 3, 
7 and weekly thereafter until transfer (to another ward, another healthcare institution), discharged 
from the hospital (to home) or death. 
Firstly, rectal swabs were sent for the identification of CPE positive samples using chromogenic 
screening media at National Health Laboratory Service (NHLS). Antibiotic susceptibility testing 
was also conducted to evaluate the antibiogram of CPEs and confirm the minimum inhibitory 
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concentrations (MICs) using the VITEK II automated method, and the findings were interpreted 
according to EUCAST guidelines (https://eucast.org/clinical_breakpoints/). 
Genomic DNA was extracted using GenElute bacterial genomic DNA Kit (Sigma-Aldrich, St. 
Louis, MO, USA) according to the manufacturer's instructions for further molecular tests. 
Enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) was used to determine the 
genetic fingerprints to assess the relatedness of CPEs in the ICU. Representative isolates showing 
a similar antibiogram and also belonging to the same ERIC profile from each patient, were sent 
for WGS applying an Illumina MiSeq platform at the National Institute for Communicable 
Diseases (NICD), Johannesburg, South Africa. Assembled genomes were annotated using the 
Centre for Genomic Epidemiology (CGE) tools to reveal resistance genes, type plasmid replicons, 
and draw phylogenetic trees, using ResFinder, PlasmidFinder, and CSIPhylogeny respectively. 
The presence of transposases, integrons, and other genomic characteristics were detected by RAST 
SEED viewer. MobileElementFinder was used to infer insertion sequences (ISs). Multi-locus 
sequence type (MLST) was established using PubMLST server and serotypes were predicted using 
Kaptive website. Virulence genes and virulence factors were detected using BacWGSTdb and 
Pathogenwatch servers, respectively. 
1.5 Dissertation Structure 
This study aimed to investigate the molecular epidemiology of CPEs colonizing and/or infecting 
patients in a general ICU of a public sector regional hospital, in the uMgungundlovu district. The 
research is presented in three chapters as follows: 
Chapter 1 provides the introduction, literature review, aims, and objectives as well as summary of 
the methodology used. 
Chapter 2 presents the investigations and findings in manuscript format prepared for submission 
to the Journal of Hospital Infection. 
Chapter 3 includes conclusions, limitations, and recommendations for future research. 
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Background: Due to the high association with mortality and morbidity, carbapenem-resistant 
Enterobacterales (CRE) in general, and carbapenem-resistant Klebsiella pneumoniae, in 
particular, have been listed as high-priority pathogens by the World Health Organization (WHO) 
for the research and development of new antibiotics. Concomitant resistance to multiple antibiotics 
of different classes, impedes efficient clinical management of CRE infections. We characterized 
carbapenemase-producing K. pneumoniae (CPKP) isolates from sequential rectal screening of 
patients in a single intensive care unit (ICU) in a public hospital in the uMgungundlovu District of 
Kwazulu-Natal, South Africa, collected over one month. Method: Ninety-seven rectal swabs 
collected from all consenting adult patients (n=31) on day 1, 3, 7 and weekly thereafter were 
screened for carbapenemase-production using Chrome-ID selective media. Fourteen CPKP were 
subjected to speciation and antibiotic susceptibility testing using the VITEK 2® automated system 
and their clonality was ascertained by ERIC/PCR. A sub-sample of eight isolates from five patients 
underwent whole genome sequencing (WGS) on the Illumina MiSeq platform followed by 
bioinformatics analysis to delineate the resistome, virulome, mobilome, clonality and phylo-
geography. Results: All isolates (100%) were resistant to ertapenem and meropenem and 71.4% 
(n=10) were resistant to imipenem. All isolates harbored the blaOXA-181 carbapenemase (100%, 
n=8) and also carried other β-lactamase genes such as OXA-1, CTX-M-15, TEM-1B and SHV-1. 
IncF, IncX3, and Col plasmid replicons groups and class I integrons (ln191 and ln27) were 
detected. All isolates belonged to the same sequence type ST307 and capsular serotypes (K102, 
O2v2) and several were associated with a single bed located in the ICU. All but one isolate carried 
the same plasmid multilocus sequence type [K7:A-:B-] and the same virulence repertoire was 
identified reflecting the epidemiological relationships between isolates. BlaOXA-181 were 
presumably located on a multi-replicon plasmid similar to that of E. coli p010_B-OXA181, and 
isolates were aligned with several South African and international clades, demonstrating horizontal 
and vertical transboundary distribution. Conclusion: OXA-181-producing K. pneumoniae 
belonging to ST307 was found to be potentially endemic in the hospital ICU environment of a 
public hospital in KwaZulu-Natal South Africa. The presence of a myriad of antibiotic resistance 
genes (ARGs) and mobile genetic elements (MGEs) in different permutations and combinations 
presents challenges to clinical management and infection prevention and control measures. This 
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necessitates a CRE screening programme and strict infection prevention and control measures to 
detect and eliminate this endemic clone. 
Keywords 
Carbapenem resistance; Enterobacterales; Klebsiella pneumoniae; whole genome sequencing; 
South Africa 
Introduction 
β-lactams are one of the most prescribed antibiotics globally (Klein et al., 2018), in part because 
they are flexible and can be structurally modified to result in several active forms, a malleability 
not possessed by other antibiotic classes (Bush and Bradford, 2016). Carbapenems, among the β-
lactams, are effective against Gram-positive and Gram-negative bacteria, providing a broad 
spectrum of antibacterial activity. A particular molecular structure, along with the β-lactam ring, 
gives added stability to most β-lactamases including extended-spectrum β-lactamases (ESBLs), 
making carbapenems "last-resort antibiotics" or "last-line agents" for critically ill patients 
suspected of drug-resistant infections treatment (Ramsamy et al., 2020). The widespread use of 
carbapenems for the multidrug-resistant bacterial infections has contributed to the development of 
resistance, most frequently mediated by β-lactamases, called carbapenemases (Pitout, Nordmann 
and Poirel, 2015). Less common resistance mechanisms include altered target penicillin binding 
proteins (PBPs) or reduced cell entry due to upregulated efflux pumps or modifications in the outer 
membrane proteins (Bush and Bradford, 2020). 
Carbapenemases belong to the Ambler class A (e.g., KPC, SME, IMI, and GES), class B (e.g., 
NDM, VIM, and IMP), and class D (OXA-48–like). The carbapenemases of class A and class D 
are serine β-lactamases, and the carbapenemases of class B are metallo-β-lactamases (MBLs) (Cui, 
Zhang and Du, 2019). Class B carbapenemases, particularly blaNDM, are more potent than other 
classes and cannot be inhibited by β-lactamase inhibitors (BLIs) such as clavulanic acid, 
tazobactam, or sulbactam (Somboro et al., 2018). OXA carbapenemases, and specifically 
blaOXA-48 has a more restricted spectrum of β-lactam hydrolysis with clinically significant 
penicillin and imipenem hydrolysis and lower meropenem hydrolysis (Bush and Bradford, 2020). 




Carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa and Acinetobacter 
baumannii are listed by the World Health Organization (WHO) as high priority pathogens for the 
research and development of new antibiotics (World Health Organization, 2017). Serious CRE 
infections have a higher risk of fatality than those caused by carbapenem-sensitive isolates (Martin 
et al., 2018). This threat is considerably higher when the carbapenem resistance in 
Enterobacterales is due to carbapenemase production (CPEs). Compared with the non-CPE 
infections (n=37,45%), CPE infections (n=46, 55%) were reported to cause four times the risk of 
death within 14 days among hospitalized patients in an academic hospital in the USA between 
March 2013 and April 2016 (Tamma et al., 2017). 
Carbapenemase resistance genes are associated with diverse mobile genetic elements (MGEs) 
including but not limited to plasmids, transposons, and integrons (Lynch et al., 2016). IncF plasmid 
replicons are the most common and are primarily reported to bear the blaKPC and blaNDM genes 
in the United States, Greece, Canada, Taiwan, and South Africa (Pedersen et al., 2018). The 
transposon Tn125, harbouring the insertion element ISAba125, is recognized as the primary 
vehicle for disseminating NDM-1 enzymes in Acinetobacter baumannii (Khan, Maryam and 
Zarrilli, 2017). The successful propagation of OXA-48 is linked with different Tn1999 variants on 
highly transferable IncL plasmids, strengthened by the global distribution of specific high-risk 
clones such as K. pneumoniae ST307 (Pitout et al., 2019). 
Klebsiella pneumoniae is an invasive and virulent bacterium among Enterobacterales that 
harbours multiple antibiotic resistance genes (ARGs) (Partridge, 2011). K. pneumoniae easily 
assimilate ARGS by horizontal gene transfer (HGT) of MGEs (Mathers, Peirano and Pitout, 2015). 
The increase in multidrug-resistant (MDR) K. pneumoniae and especially carbapenem-resistant K. 
pneumoniae (CRKP), is of significant medical concern. A recent meta-analysis approximated 
mortality associated with K. pneumoniae health care associated infections (HAI) at 42% for CRKP 
compared with 21% for carbapenem-susceptible strains (Xu, Sun and Ma, 2017). 
We used whole genome sequencing (WGS) and bioinformatics analysis to characterize CPE 
implicated in the colonization of patients in an intensive care unit (ICU) of a public hospital in the 
uMgungundlovu district, KwaZulu-Natal, South Africa. Isolates were a sub-sample of a larger 
study investigating the incidence and transmission of CPEs among ICU patients receiving 
carbapenem treatment in three hospitals. 
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Materials and methods 
Ethical considerations 
This study was approved by the UKZN Biomedical Research Ethics Committee (BREC) (Ref No 
BE709/18 and BREC/00001723/2020). 
Permission was granted by the KwaZulu-Natal Department of Health, the uMgungundlovu District 
Manager, the hospital Chief Executive Officer and ICU Manager. Voluntary informed consent was 
obtained from patients themselves, from their next of kin, or proxy consent was obtained from the 
ICU manager. 
Study population and settings 
This was a descriptive sub-study on isolates collected from a larger PhD study, conducted in three 
hospitals in the public and private healthcare system in uMgungundlovu district that investigated 
the incidence and transmission of CPEs among ICU patients receiving carbapenem treatment. The 
sub-study focused on isolates obtained from ICU patients of one study hospital, from February 
2020 and March 2020. This study's participants were all consenting adult patients admitted over 
one month into the general ICU (medical and surgical) of a regional public hospital. 
Sample collection 
Patients were screened for CPE using rectal swabs on day 1, 3, 7 and weekly thereafter until 
transfer (to another ward or healthcare institution), discharge or death. 
Laboratory analysis 
Screening for CPEs 
Ninety-seven rectal swabs from 31 patients were screened for CPE using chromogenic screening 
media Chrom-ID CARBA SMART according to manufacturer instructions (BioMérieux, Marcy 
l’Étoile, France). Fourteen samples that tested positive for CPEs (14.4% of total samples) from 
five patients (16% of total patients enrolled) formed the final sample. 
Antimicrobial susceptibility testing (AST) 
Identification of the isolates to species levels and antibiotic susceptibility testing was conducted 
using the VITEK 2® automated system (BioMérieux-Vitek, Marcy-l'Étoile, France), and results 
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were interpreted according to the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) breakpoints. The antibiotic panel consisted of 18 antibiotics: ampicillin (AMP), 
amoxicillin-clavulanic acid (AMC), piperacillin-tazobactam (TZP), cefuroxime (CXM), 
cefuroxime-axetil (CXM-AX), cefoxitin (FOX), cefotaxime (CTX), ceftazidime (CAZ), cefepime 
(FEP), ertapenem (ERT), imipenem (IPM), meropenem (MEM), amikacin (AMK), gentamicin 
(GEN), ciprofloxacin (CIP), tigecycline (TGC), nitrofurantoin (NIT), and trimethoprim-
sulfamethoxazole (SXT). 
Genomic characterization 
DNA extraction of CPKP isolates 
Genomic DNA was extracted using GenElute bacterial genomic DNA kit (Sigma-Aldrich, St. 
Louis, MO, USA) according to the manufacturer's instructions for further molecular tests. 
IncoTherm digital incubator (Labotec, Cape Town, South Africa) and Heraeus Biofuge Pico 
centrifuge (DJB Labcare Ltd, Bucks, England) were used in this process. Extracted DNA was 
checked for suitable concentrations and purity using Nanodrop 8000 spectrophotometer (Thermo 
Scientific, Waltham, MA, USA). 
Genomic fingerprinting 
Clonality was investigated using enterobacterial repetitive intergenic consensus-PCR (ERIC-
PCR). The primers ERIC1 (52-ATGTAAGCTCCTGGGATTCAC-32) and ERIC2 (52-
AAGTAAGTG ACTGGGTGAGCG-32) (Inqaba Biotech (Pty.) Ltd., Pretoria, South Africa), 
were used to perform ERIC-PCR reactions (Chukwu et al., 2019) on a T100 Thermal Cycler (Bio-
Rad, Hercules, CA, USA) with a total volume of 25 μL consisting of 12.5 μL of Dream Taq Green 
PCR Master Mix (2X) (ThermoFisher Scientific, Waltham, MA USA), 0.1 μL (100 μM) of each 
primers ERIC1 and ERIC2, 8.3 μL of nuclease-free H2O and 4 μL of total genomic DNA. The 
PCR conditions were initial denaturation at 94°C for 3 min, followed by 29 cycles denaturation at 
94°C (30 s), annealing at 50°C (1 min), an extension at 65°C (8 min), and a final extension at 65°C 
(16 min). PCR amplicons were resolved horizontally by electrophoresis on 1.5% (w/v) on 
SeaKem® LE agarose gel at 90V for two hours (Lonza, Rockland, ME, USA) followed by staining 
in 0.1 mg/ml of ethidium bromide for 15 minutes. The Quick-load®1-kb DNA ladder (New 
England Biolabs, Ipswich, Massachusetts, USA), a positive control (K. pneumoniae ATCC BAA-
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1705) and a "no template control (NTC)" were included in these reactions. The gel was visualized, 
and the images captured under ultraviolet light using the Gel DocTM XR+ system (Bio-Rad, 
Hercules, CA, USA). Data was exported to Bionumerics software (version 7.6, Applied Maths, 
TX, USA) for cluster analysis. Strains were allocated to various clusters by evaluating the 
similarity coefficient from the homology matrix using the Jaccard approach. Dendrograms were 
assembled using the Unweighted Pair-Group Method (UPGMA). A 1% optimization and band 
tolerance (version 7.6, Applied Maths, TX, USA) were set, and 80% cut-off similarity was used 
to identify clusters. 
Whole-genome sequencing of CPKP isolates 
A sub-sample of ten isolates, one per patient, was chosen on the basis of similar antibiograms and 
ERIC profiles and subjected to whole genome sequencing on the Illumina MiSeq platform. Using 
the Nextera XT DNA sample preparation kit (Illumina, San Diego, CA, USA), multiplexed paired-
end libraries (2300 bp) were prepared, and sequences were measured on 100-coverage. Utilizing 
CLC Genomics Workbench version 10, the resulting raw reads were screened for quality, trimmed, 
and de novo assembled into contigs (CLC, Bio-QIAGEN, Aarhus, Denmark) (Bankevich et al., 
2012). Two isolates were removed for poor DNA quality. 
Genomic analyses and annotation 
The National Centre for Biotechnology Information (NCBI) prokaryotic genome annotation 
pipeline (PGAP) and RAST 2.0 server (Tatusova et al., 2016) were used to annotate assembled 
reads. All contiguous sequences were subsequently submitted to GenBank and assigned accession 
numbers under the Bioproject (PRJNA674742). ARGs were detected using ResFinder (Zankari et 
al., 2012) and plasmids were delineated using PlasmidFinder (Carattoli et al., 2014), respectively. 
The RAST SEED viewer (Overbeek et al., 2014) was employed to detect the genomic 
characteristics of the contigs, and the presence of transposases flanking the β-lactamase genes (or 
carbapenemases). The INTEGRALL database was used to assess integrons present 
(http://integrall.bio.ua.pt/). Insertion sequences (IS) residing in genomes were inferred by 
uploading contigs to the MobileElementFinder (Johansson et al., 2021). The BacWGSTdb and 
Pathogenwatch servers were employed to infer Virulence genes and factors 
(http://bacdb.cn/BacWGSTdb/, https://pathogen.watch/). Kaptive-web, the reference online site 
tool for Klebsiella WGS data, was used to predict isolate serotypes (K types, wzc and wzi allelic 
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types, and O types) (Wyres and Holt, 2016). Multi-locus sequence type (MLST) analyses were 
performed to determine sequence types (STs) of our K. pneumoniae isolates on the PubMLST 
database (https://pubmlst.org/). 
Detection of BlaOXA-181 plasmid-encoding 
The carbapenemase genes and their flanking sequences retrieved from the RAST SEED viewer 
were searched on the NCBI microbial nucleotide basic local alignment search tool (BLAST). Fully 
sequenced plasmids with the closest synteny obtained from the BLAST search were used as a 
reference input to GView Server (https://server.gview.ca/) to visualize the presumed 
presence/absence of specific plasmid DNA. 
Phylogenetics 
Phylogenomic analysis was undertaken to determine how our isolates compare to K. pneumoniae 
genomes from South Africa. All K. pneumoniae genomes reported in South Africa (n=89) were 
downloaded from the PATRIC website (https://www.patricbrc.org/), annotated (Table S1) and 
included in the analysis. The phylogenetic tree was constructed based on the maximum likelihood 
method using the CSIPhylogeny (https://cge.cbs.dtu.dk/services/CSIPhylogeny/) (Kaas et al., 
2014) which performs single nucleotide polymorphism (SNP) calling, filters the SNPs, and infers 
phylogeny based on the concatenated alignment of the high-quality SNPs, using the assembled 
contigs. The analysis was performed on the platform using default parameters as follows: 
minimum depth at SNP positions, 10X; minimum relative depth at SNP positions of 10%; 
minimum distance between SNPs (prune) at 10bp; minimum SNP quality, 30; minimum read 
mapping quality of 25 and minimum Z-score of 1.96. The Escherichia coli ATCC 25922 was used 
as the outgroup strain (reference genome), facilitating the configuration of the phylogenetic 
distance between the isolates on the branches. The Figtree software 
(http://tree.bio.ed.ac.uk/software/figtree/) was used visualize edit and annotate the generated 
phylogenetic tree. 
Nucleotide sequence accession numbers 
The nucleotide sequences of the eight isolates analysed in this study were deposited in NCBI 
GenBank database in the Bioproject number (PRJNA674742): under the Accession numbers; 
JADKPL000000000.1, JADOEH000000000.1, JADOEG000000000.1, JADKPK000000000.1, 
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Of the five consenting adult patients that screened positive for CPE, three were males, while two 
patients were females, with age ranging from 26 to 64 years old and a mean age of 45. Although 
they were admitted to the ICU with different diagnoses, almost all had the same invasive devices. 
The relevant patient’s data appears in Supplementary Table S2. 
Antimicrobial resistance profiles 
Isolates showed a similar resistance patterns to the panel of antibiotics. All isolates (100%) were 
resistant to 14 antibiotics, viz., ampicillin, amoxicillin-clavulanic acid, piperacillin-tazobactam, 
cefuroxime, cefuroxime-axetil, cefoxitin, cefotaxime, ceftazidime, cefepime, ertapenem, 
meropenem, ciprofloxacin, nitrofurantoin, and trimethoprim-sulfamethoxazole. However, they 
were fully susceptible to tigecycline and amikacin. Twelve (85,7%) of isolates were susceptible to 
gentamycin and 28.6% (n=4) were susceptible to imipenem. All isolates were MDR and the 
resistance phenotype was confirmed by the ARGS detected by WGS (Figure 2). 
Genomic fingerprint 
The ERIC dendrogram showed five main clusters. Isolates belonging to the same ERIC cluster 
generally had similar antibiograms, except for ERIC cluster 2 where isolates exhibited two 
antibiograms. Patients generating more than one CPE sample carried isolates belonging to 2-4 
different ERIC clusters (e.g., isolates 13, 22 and 30) (Figure 1, Table 1). 
Genomes characteristics 
The draft genomes sizes of the eight isolates subjected to WGS and bioinformatics analysis were 
similar and ranged from 5.58 Mb to 5.72 Mb. The (G+C) content was the similar for all isolates 
(57.1) except 2 that differed slightly in terms of median contig lengths (N50, L50), contigs, RNAs 
present, and number of coding sequences (Table S3). 
In silico ARGs 
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The genomic data (resistomes) confirmed the resistance phenotypes in most isolates (Table 1). 
Anomalies were detected for aminoglycosides where the presence of the aadA1 (n=2), aadA2 
(n=1), aac(6')-Ib-cr (n=8), aph(3'')-Ib (n=5), aph(3')-Ia (n=2), aph(3')-Via (n=2), armA (n=2), 
aph(6)-Id (n=5), aac(3)-Ia (n=1) aminoglycoside ARGs did not translate into phenotypic 
aminoglycoside resistance on AST. A single carbapenemase gene (blaOXA-181) was common to 
all isolates. Five other β-lactamase were detected [blaCTX-M-15, blaOXA-1, blaSHV-106] (n=8), 
blaTEM-1B (n=7), and blaTEM-1C (n=1). Carbapenemases from classes A, B, and C were not 
detected. Other ARGs detected conferred resistance to tetracyclines [tet(A)] (n=7), 
fluoroquinolones [aac(6’)-lb-cr, oqxA, oqxB, qnrB1, qnrS1] (n=8), trimethoprim [dfrA12 (n=1), 
dfrA14 (n=7)], sulphonamides [sul1 (n=1), sul2 (n=5)], fosfomycin (fosA) (n=8), macrolides 
[msr(E) (n=2), mph(E) (n=2)], phenicols [catB3 (n=8), cmlA1 (n=2)], rifamycin (ARR-2) (n=1) 
and streptogramin b [msr(E) (n=2)]. 
Sequence types analysis (MLST) and in silico mobile genetic elements (Mobilome) 
All isolates belonged to ST307 (Table 1). Plasmid analysis showed that each isolate harboured at 
least two replicon types simultaneously (Table 2). All isolates carried ColKP3 and 6, 7 and 6 
isolates carried the IncX3, IncFIB (K) and IncFII (K) replicons respectively. One isolate carried 
the IncFIB (pNDM-Mar) from the same group. The search for carbapenemase (OXA-181) and its 
flanking sequences using NCBI microbial nucleotide BLAST showed that it was located on a multi 
replicon plasmid E. coli p010-B-OXA181 (accession no.: CP048332.1). The presence of genome 
assemblies with similar genetic synteny and 99.98% coverage and identity to the E. coli p010 B-
OXA181 reference was confirmed by comparative analyses through the GView server (Figure 3) 
intimating the location of OXA-181 on a similar plasmid in our CPKP isolates. 
We tried to determine the location of ARGs & MGEs in synteny in our isolates on plasmids and 
chromosomes on the NCBI databases, which led us to assume their location on the plasmid 
replicons we identified except for one β-lactamase gene, blaSHV-106, that was associated with a 
chromosomal location (Table 3). It is noteworthy that the ISKpn19 insertion sequence containing 
the OXA-181 concurrently harboured the EreA and QnrS1 genes in seven of the eight isolates 
together with recombinase and transposases. One isolate carried the same insertion sequence but 
was located on transposon (Tn3-like IS3000 transposase), found in the same plasmid and with the 
same companions (Table 3, Figure 4). 
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We further identified blaSHV-106 on all isolates in parallel with other β-lactamase genes viz., 
blaOXA-1, blaCTX-M-15, blaTEM-1B, and blaTEM-1C in various permutations and 
combinations, the synteny of which was closely related to plasmid sequences already described in 
Genbank and summarised in Table 3. Across the isolates, blaCTX-M-15 (bracketed by Tn3 
transposon, IS6100 and ISEc9), most of blaTEM-1B genes (bracketed by IS91, and a 
recombinase), and most of aph(6)-Id, aph(3”)-Ib, sul2 genes (bracketed by IS91, IS5070 and IS5) 
were found in close synteny on the same plasmids, except for one isolate (EC03612985) that 
encoded both blaCTX-M-1 and blaTEM-1C on one insertion sequence (ISEc9) showing a slightly 
different genetic environment (Table 3). 
All isolates had trimethoprim and aminoglycoside resistance genes located on a class 1 integron 
(In191) in six isolates with five isolates also containing the dfra14 genes on gene cassettes. Another 
class 1 integron (In27), was detected in only one isolate and contained the dfrA12-gcuF-aadA2 
cassette arrays. Only one isolate did not have any integrons with aminoglycosides or trimethoprim 
resistance genes (Table 2). 
Virulome 
All isolates carried the identical repertoire of 65 virulence genes. The virulome was not clone 
specific in that isolates clustered in different clades had the same virulence genes. 
The K- loci and O- loci results (KL102, 939, 173, and O2v2) were identical and showed no clonal 
specificity in our isolates. 
Phylogenetic analysis 
Although all eight isolates belonged to the same sequence type, ST307, small differences were 
evident from their phylogenetic tree, (Figure 5). When compared to genomes of K. pneumoniae 
isolates from studies conducted in Durban, Pretoria, Pietermaritzburg, Ozwatini, and Cape Town 
(Table S1), our isolates showed greatest similarity to the clade of ST307 from Pretoria and Cape 
Town (clade VIII) with one ST25 clustered close to the ST307 clade (Figure 5). 
Discussion  
The global spread of CPE presents a significant challenge to public health and clinical practice as 
these bacteria are resistant to last-resort antibiotics (carbapenems) and cause high fatality rates 
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(Sheu et al., 2019). WGS data for eight CPKP strains isolated between February 2020 and March 
2020 from patients at a general ICU of a regional hospital in uMgungundlovu District in Durban, 
South Africa, was analysed to delineate the genetic context of carbapenem resistome and 
associated mobilome together with the broader resistome, virulome, clonality and phylogeny. 
K. pneumoniae is an established and significant pathogen in nosocomial infections. MDR and 
extremely drug-resistant (XDR) K. pneumoniae is closely linked to ARGs acquired via plasmids 
and other MGEs, resulting in a 'super resistome' (Navon-Venezia, Kondratyeva and Carattoli, 
2017). 
CRKP has been implicated in outbreaks in South Africa and appears to be endemic to certain 
hospitals and regions. In May 2012, a tertiary academic hospital in Cape Town reported one of the 
first laboratory-confirmed outbreaks of K. pneumoniae expressing OXA-181 in South Africa 
linked to two patients admitted to the haematology ICU. Laboratory records before that date and 
the results of 340 rectal swabs or stool specimens collected from patients and staff members 
revealed an “outbreak” involving eight patients. Seven of them were admitted to the haematology 
unit during their hospitalization period. The remaining patient was epidemiologically linked to 
another patient because he was admitted to a bed adjacent to him (Jacobson et al., 2015). 
The identification of ARGs from WGS data correlated with the phenotypic resistance observed in 
most instances in our study, with resistance ranging from 14% to 100%. However, some anomalies 
were observed, in particular, for aminoglycosides, where the presence of aminoglycoside ARGs 
on WGS were not phenotypically evident, intimating transcriptionally silent or unexpressed ARGs. 
All isolates belonged to the same ST type and the same phylogenetic clade suggesting an endemic 
strain in the ICU. Additionally, all patients occupying a particular bed (bed 5) in the ICU belonged 
to the same ERIC cluster indicating the hospital environment as a potential source of colonization 
(Figure 1, Table S2). 
Our findings showed that the CPKP hospital population was not diverse and belonged to a single 
sequence type (ST307) (Table 1), clade and capsular serotype and contained identical repertoires 
of virulence genes). The phylogeography analysis with South African K. pneumonia isolates 
showed our isolates clustering in clade VIII similar to isolates from Pretoria and Cape Town 
(Figure 5). The Pretoria study characterized the resistome, mobilome, methylome, virulome, and 
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phylogeography of 56 CRKP with reduced susceptibility to carbapenems from six public hospitals 
and centers in the Tshwane District in 2018. The K. pneumoniae isolates belonged to ST307 and 
had similar resistance determinants, particularly, OXA-181 along with OXA-1, TEM-1B, CTX-
M-15, and blaSHV-28 genes. Moreover, similar  plasmid (Inc) types [ColKP3,IncX3,IncFIB 
(k),IncFII (k)] and serotypes (KL102, O2v2) were evident (Kopotsa, Mbelle and Sekyere, 2020), 
suggesting that the same strain is circulating in the Kwazulu-Natal area. 
Klebsiella pneumoniae ST307 is a relative newcomer to successful high-risk antibiotic resistant 
strains contributing to a significant global public health burden. It possibly originated in Europe 
during the early to mid-1990s but was first published in the MLST database from the Netherland 
in 2008 (https://bigsdb.pasteur.fr/klebsiella/klebsiella.html). The earliest published reports came 
from the USA (Castanheira et al., 2013) and Pakistan (Habeeb et al., 2013) in 2013 and were 
followed by reports from different countries including from Russia (Lazareva et al., 2016), Spain 
(Ruiz-Garbajosa et al., 2016), Brazil (Dropa et al., 2016), and Japan (Harada et al., 2016) during 
2016. The global distribution of K. pneumoniae ST307 has been recorded from all continents, 
except Antarctica and has been implicated in many nosocomial (Baek et al., 2020) and long-term 
care centre outbreaks. Findings from Colombia (Ocampo et al., 2016), Texas, the United States 
(Long et al., 2017), Argentina (Cejas et al., 2019), and Italy (Bonura et al., 2015) have also shown 
that the incidence of ST307 among CPKP has been rising over the years, even replacing other 
high-risk antibiotic resistant strains , including ST258 in regions such as Italy and Colombia 
(Bonura et al., 2015; Ocampo et al., 2016). 
A recent study examined major nationwide nosocomial outbreaks of blaOXA-181 and blaCTX-
M-15 within several South African provinces. blaOXA-181 was reported in 471 K. pneumoniae 
isolates belonging to ST307, isolated from 1,247 unique clinical isolates from a private laboratory 
network repository over the period 2014–2016. Bayesian evolution analysis showed that ST307 
isolates have evolved into six clades with clades I - IV restricted to Texas in the United States and 
clade VI confined to South Africa. Clade V is, in contrast, globally distributed. Clade VI in South 
Africa originated in 2013, and developed into two distinct lineages during 2014 spreading over a 
span of 15 months, across 23 cities/towns in six provinces of South Africa (Lowe et al., 2019). 
Several carbapenemases have been identified in K. pneumoniae in South Africa. Lowe and 
colleagues (2019) reported an exponential increase in blaOXA-48 like producing K. pneumoniae 
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in contrast to two studies in 2016 that detected blaNDM-1 in higher amounts than blaOXA-48. In 
2016, Perovic and colleagues reported data from private sector laboratories in South Africa, where 
a high prevalence of blaNDM-1 was observed in Gauteng province compared to blaOXA-48 
through an evaluation of 9029 Gram-negative ESKAPE (E. faecium, E. faecalis, S. aureus, K. 
pneumoniae, A. baumannii, P. aeruginosa, E. cloacae and E. coli) isolates (Perovic et al., 2018). 
A review in the same year (2016), assessing carbapenem resistance-reporting publications from 
January 2000 and May 2016, showed that most common carbapenem-resistant isolates were 
isolated in Enterobacterales such as K. pneumoniae, E. cloacae, and S. marcescens with NDM 
(n=860) and OXA-48 (n=584) among the most reported carbapenemases (Sekyere, 2016). A recent 
report described another increment in the blaOXA-48-like producing K. pneumoniae strains, 
where blaOXA-48 (65%), followed by blaNDM-1(29%), was the most common carbapenemases 
detected (Kopotsa, Mbelle and Sekyere, 2020), in contrast to our study where OXA-181 was 
dominant.  blaNDM-1 to blaOXA-48 that has also been identified in the provinces of Gauteng and 
Eastern Cape (Perovic et al., 2018). 
Our isolates carried carbapenemase blaOXA-181, other β-lactamases, plasmid-mediated 
quinolone resistance (PMQR) genes and other ARGs conferring resistance to several antibiotic 
classes (Table 3, Figure 4), suggesting co-selection of resistance genes, and more importantly, 
HGT (Asante and Sekyere, 2019) via plasmids and other MGEs (Partridge et al., 2018; Kopotsa, 
Sekyere and Mbelle, 2019). 
blaCTX-M-15 was located on ISEc9 in all isolates, and most of blaTEM-1B on IS91 (Table 3). 
This observation that was detected globally, demonstrates the clonal and plasmid-mediated 
distribution of these ARGs within the same genetic context and on the same plasmid replicons in 
the same and different species. For example, IncF plasmids and ISEc9 have been shown to promote 
the global spread of blaCTX-M-15, alongside blaOXA-10, aac(6′)Ib-cr, and blaTEM, across 
different species (Kopotsa, Sekyere and Mbelle, 2019). The presence of these genes in similar 
genetic contexts were reported in another South African study describing 20 consecutive MDR E. 
coli isolates collected from a referral laboratory serving two secondary and three tertiary academic 
hospitals in Gauteng province. The study reported ARGs mediating resistance to fluoroquinolones, 
aminoglycosides, and tetracyclines in E. coli isolates alongside β-lactam resistance mediated by 
OXA, CTX-M, and TEM-1B. Many of these resistance determinants were located on contigs 
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containing multiple plasmid replicons and bracketed by composite transposons (Tn3), various ISs, 
and class 1 integrons. IncF was the most common plasmid replicon, class 1 integrons were the 
only integron type identified and blaCTX-M genes was frequently detected in ISEc9 (Mbelle et 
al., 2019), similar to our findings. 
The diverse mobilome consisting of different plasmid replicons [ColKP3, IncFIB(K), IncFII(K), 
IncFIB(pNDM-Mar), and IncX3] (Table 2) and insertion sequences (Table 3) intimates the 
potential mobility of this blaOXA-181 by HGT among isolates. Furthermore, the global 
dominance of the IncF plasmid, an HGT-associated MGE, is verified in previous studies. For 
instance, Pedersen and colleagues confirmed the role of MGEs in the potential distribution of 
carbapenemases. They investigated the molecular epidemiology of CRE clinical samples (n=45) 
collected by a private laboratory in Durban from hospitalized patients in 10 separate private 
hospitals between 2012 and 2013. Focusing on the carbapenem-resistance encoding determinants 
and their genetic support, they demonstrated patterns of dissemination of CPE gens (blaNDM-1, 
blaGES-5, blaOXA-232, and blaNDM-5) via MGEs (e.g., integrons and insertion sequences) 
embedded in five different plasmids have been revealed to mediate their horizontal transfer, 
together with clonal transmission, between various Enterobacterales species (Pedersen et al., 
2018).  
Conclusion 
OXA-181-producing K. pneumoniae belonging to ST307 was found to be potentially endemic in 
the hospital ICU environment of a public hospital in KwaZulu-Natal South Africa. The presence 
of a myriad of ARGs and/or MGEs in different permutations and combinations presents challenges 
to clinical management and infection prevention and control measures. This necessitates a CRE 
screening programme and strict infection prevention and control measures to detect and eliminate 
this endemic clone. 
References 
ASANTE, J. and SEKYERE, J. O. 2019. Understanding antimicrobial discovery and resistance from a 
metagenomic and metatranscriptomic perspective: advances and applications. Environmental 
Microbiology Reports, 11, 62-86. 
BAEK, E.-H., KIM, S.-E., KIM, S., LEE, S., CHO, O.-H., HONG, S. I., SHIN, J. H. and HWANG, I. 2020. Successful 
control of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae ST307 
outbreak in a neonatal intensive care unit. Bio Medical Central Infectious Diseases, 20, 1-8. 
54 
 
BANKEVICH, A., NURK, S., ANTIPOV, D., GUREVICH, A. A., DVORKIN, M., KULIKOV, A. S., LESIN, V. M., 
NIKOLENKO, S. I., PHAM, S. and PRJIBELSKI, A. D. 2012. SPAdes: a new genome assembly algorithm 
and its applications to single-cell sequencing. Journal of Computational Biology, 19, 455-477. 
BONURA, C., GIUFFRÈ, M., ALEO, A., FASCIANA, T., DI BERNARDO, F., STAMPONE, T., GIAMMANCO, A., 
PALMA, D. M., MAMMINA, C. and GROUP, M.-G. W. 2015. An update of the evolving epidemic of 
bla KPC carrying Klebsiella pneumoniae in Sicily, Italy, 2014: emergence of multiple non-ST258 
clones. Plos One, 10, 1-9. 
BUSH, K. and BRADFORD, P. A. 2016. β-Lactams and β-lactamase inhibitors: an overview. Cold Spring 
Harbor Perspectives in Medicine, 6, 1-23. 
BUSH, K. and BRADFORD, P. A. 2020. Epidemiology of β-Lactamase-producing pathogens. Clinical 
Microbiology Reviews, 33, 1-37. 
CARATTOLI, A., ZANKARI, E., GARCÍA-FERNÁNDEZ, A., LARSEN, M. V., LUND, O., VILLA, L., AARESTRUP, F. 
M. and HASMAN, H. 2014. In silico detection and typing of plasmids using PlasmidFinder and 
plasmid multilocus sequence typing. Antimicrobial Agents and Chemotherapy, 58, 3895-3903. 
CASTANHEIRA, M., FARRELL, S. E., WANGER, A., ROLSTON, K. V., JONES, R. N. and MENDES, R. E. 2013. 
Rapid expansion of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals due to 
clonal spread of ST258 and ST307 lineages. Microbial Drug Resistance, 19, 295-297. 
CEJAS, D., ELENA, A., NUÑEZ, D. G., PLATERO, P. S., DE PAULIS, A., MAGARIÑOS, F., ALFONSO, C., BERGER, 
M. A., FERNÁNDEZ-CANIGIA, L. and GUTKIND, G. 2019. Changing epidemiology of kpc-producing 
klebsiella pneumoniae in Argentina: emergence of hypermucoviscous st25 and high-risk clone 
st307. Journal of Global Antimicrobial Resistance, 18, 238-242. 
CHUKWU, M. O., ABIA, A. L. K., UBOMBA-JASWA, E., OBI, L. C. and DEWAR, J. B. 2019. Antibiotic resistance 
profile and clonality of E. coli isolated from water and paediatric stool samples in the north-west, 
province South Africa. Journal of Pure and Applied Microbiology, 13, 517-530. 
CUI, X., ZHANG, H. and DU, H. 2019. Carbapenemases in Enterobacteriaceae: detection and antimicrobial 
therapy. Frontiers in Microbiology, 10, 1-12. 
DROPA, M., LINCOPAN, N., BALSALOBRE, L. C., OLIVEIRA, D. E., MOURA, R. A., FERNANDES, M. R., DA 
SILVA, Q. M., MATTÉ, G. R., SATO, M. I. and MATTÉ, M. H. 2016. Genetic background of novel 
sequence types of CTX-M-8-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae 
from public wastewater treatment plants in São Paulo, Brazil. Environmental Science and Pollution 
Research, 23, 4953-4958. 
HABEEB, M. A., HAQUE, A., NEMATZADEH, S., IVERSEN, A. and GISKE, C. G. 2013. High prevalence of 16S 
rRNA methylase RmtB among CTX-M extended-spectrum β-lactamase-producing Klebsiella 
pneumoniae from Islamabad, Pakistan. International Journal of Antimicrobial Agents, 41, 524-526. 
HARADA, K., SHIMIZU, T., MUKAI, Y., KUWAJIMA, K., SATO, T., USUI, M., TAMURA, Y., KIMURA, Y., 
MIYAMOTO, T. and TSUYUKI, Y. 2016. Phenotypic and molecular characterization of antimicrobial 
resistance in Klebsiella spp. isolates from companion animals in Japan: clonal dissemination of 
multidrug-resistant extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Frontiers 
in Microbiology, 7, 1-12. 
JACOBSON, R. K., MANESEN, M. R., MOODLEY, C., WILLIAMS, S., NICOL, M. and BAMFORD, C. 2015. 
Molecular characterisation and epidemiological investigation of an outbreak of bla OXA-181 
carbapenemaseproducing isolates of Klebsiella pneumoniae in South Africa. South African Medical 
Journal, 105, 1-6. 
JOHANSSON, M. H., BORTOLAIA, V., TANSIRICHAIYA, S., AARESTRUP, F. M., ROBERTS, A. P. and PETERSEN, 
T. N. 2021. Detection of mobile genetic elements associated with antibiotic resistance in 
Salmonella enterica using a newly developed web tool: MobileElementFinder. Journal of 
Antimicrobial Chemotherapy, 76, 101-109. 
55 
 
KAAS, R. S., LEEKITCHAROENPHON, P., AARESTRUP, F. M. and LUND, O. 2014. Solving the problem of 
comparing whole bacterial genomes across different sequencing platforms. Plos One, 9, 1-8. 
KHAN, A. U., MARYAM, L. and ZARRILLI, R. 2017. Structure, genetics and worldwide spread of New Delhi 
metallo-β-lactamase (NDM): a threat to public health. Bio Medical Central Microbiology, 17, 1-12. 
KLEIN, E. Y., VAN BOECKEL, T. P., MARTINEZ, E. M., PANT, S., GANDRA, S., LEVIN, S. A., GOOSSENS, H. and 
LAXMINARAYAN, R. 2018. Global increase and geographic convergence in antibiotic consumption 
between 2000 and 2015. Proceedings of the National Academy of Sciences, 115, E3463-E3470. 
KOPOTSA, K., MBELLE, N. M. and SEKYERE, J. O. 2020. Epigenomics, genomics, resistome, mobilome, 
virulome and evolutionary phylogenomics of carbapenem-resistant Klebsiella pneumoniae clinical 
strains. Microbial Genomics, 6, 1-19. 
KOPOTSA, K., SEKYERE, J. O. and MBELLE, N. M. 2019. Plasmid evolution in carbapenemase‐producing 
Enterobacteriaceae: a review. Annals of the New York Academy of Sciences, 1457, 61-91. 
LAZAREVA, I., AGEEVETS, V., ERSHOVA, T., ZUEVA, L., GONCHAROV, A., DARINA, M., SVETLICHNAYA, Y. S., 
USKOV, A. and SIDORENKO, S. 2016. Prevalence and antibiotic resistance of carbapenemase-
producing Gram-negative bacteria in Saint Petersburg and some other regions of the Russian 
Federation. Antibiotics and Chemoterapy, 61, 28-38. 
LOMOVSKAYA, O., SUN, D., RUBIO-APARICIO, D., NELSON, K., TSIVKOVSKI, R., GRIFFITH, D. C. and DUDLEY, 
M. N. 2017. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance 
mechanisms on activity in Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 61, 1-15. 
LONG, S. W., OLSEN, R. J., EAGAR, T. N., BERES, S. B., ZHAO, P., DAVIS, J. J., BRETTIN, T., XIA, F. and MUSSER, 
J. M. 2017. Population genomic analysis of 1,777 extended-spectrum beta-lactamase-producing 
Klebsiella pneumoniae isolates, Houston, Texas: unexpected abundance of clonal group 307. 
Journal of Clinical microbiology, 8, 1-18. 
LOWE, M., KOCK, M. M., COETZEE, J., HOOSIEN, E., PEIRANO, G., STRYDOM, K.-A., EHLERS, M. M., MBELLE, 
N. M., SHASHKINA, E. and HASLAM, D. B. 2019. Klebsiella pneumoniae ST307 with blaOXA-181, 
South Africa, 2014–2016. Emerging Infectious Diseases, 25, 739-747. 
LYNCH, T., PETKAU, A., KNOX, N., GRAHAM, M. and VAN DOMSELAAR, G. 2016. A primer on infectious 
disease bacterial genomics. Clinical Microbiology Reviews, 29, 881-913. 
MARTIN, A., FAHRBACH, K., ZHAO, Q. and LODISE, T. 2018. Association between carbapenem resistance 
and mortality among adult, hospitalized patients with serious infections due to 
Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis. Open Forum 
Infectious Diseases, 5, 1-23. 
MATHERS, A. J., PEIRANO, G. and PITOUT, J. D. 2015. The role of epidemic resistance plasmids and 
international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clinical 
Microbiology Reviews, 28, 565-591. 
MBELLE, N. M., FELDMAN, C., SEKYERE, J. O., MANINGI, N. E., MODIPANE, L. and ESSACK, S. Y. 2019. The 
resistome, mobilome, virulome and phylogenomics of multidrug-resistant Escherichia coli clinical 
isolates from Pretoria, South Africa. Scientific Reports, 9, 1-16. 
NAVON-VENEZIA, S., KONDRATYEVA, K. and CARATTOLI, A. 2017. Klebsiella pneumoniae: a major 
worldwide source and shuttle for antibiotic resistance. Federation of European Microbiological 
Societies Microbiology Reviews, 41, 252-275. 
OCAMPO, A. M., CHEN, L., CIENFUEGOS, A. V., RONCANCIO, G., CHAVDA, K. D., KREISWIRTH, B. N. and 
JIMÉNEZ, J. N. 2016. A two-year surveillance in five Colombian tertiary care hospitals reveals high 
frequency of non-CG258 clones of carbapenem-resistant Klebsiella pneumoniae with distinct 
clinical characteristics. Antimicrobial Agents and Chemotherapy, 60, 332-342. 
SEKYERE, J. O. 2016. Current state of resistance to antibiotics of last-resort in South Africa: A review from 
a public health perspective. Frontiers in Public Health, 4, 1-11. 
56 
 
OVERBEEK, R., OLSON, R., PUSCH, G. D., OLSEN, G. J., DAVIS, J. J., DISZ, T., EDWARDS, R. A., GERDES, S., 
PARRELLO, B. and SHUKLA, M. 2014. The SEED and the Rapid Annotation of microbial genomes 
using Subsystems Technology (RAST). Nucleic Acids Research, 42, D206-D214. 
PARTRIDGE, S. R. 2011. Analysis of antibiotic resistance regions in Gram-negative bacteria. Federation of 
European Microbiological Societies Microbiology Reviews, 35, 820-855. 
PARTRIDGE, S. R., KWONG, S. M., FIRTH, N. and JENSEN, S. O. 2018. Mobile genetic elements associated 
with antimicrobial resistance. Clinical Microbiology Reviews, 31, 1-61. 
PEDERSEN, T., SEKYERE, J. O., GOVINDEN, U., MOODLEY, K., SIVERTSEN, A., SAMUELSEN, Ø., ESSACK, S. Y. 
and SUNDSFJORD, A. 2018. Spread of plasmid-encoded NDM-1 and GES-5 carbapenemases 
among extensively drug-resistant and pandrug-resistant clinical Enterobacteriaceae in Durban, 
South Africa. Antimicrobial Agents and Chemotherapy, 62, 1-33. 
PEROVIC, O., ISMAIL, H., VAN SCHALKWYK, E., LOWMAN, W., PRENTICE, E., SENEKAL, M. and GOVIND, C. 
N. 2018. Antimicrobial resistance surveillance in the South African private sector report for 2016. 
Southern African Journal of Infectious Diseases, 33, 114-117. 
PITOUT, J. D., NORDMANN, P. and POIREL, L. 2015. Carbapenemase-producing Klebsiella pneumoniae, a 
key pathogen set for global nosocomial dominance. Antimicrobial Agents and Chemotherapy, 59, 
5873-5884. 
PITOUT, J. D., PEIRANO, G., KOCK, M. M., STRYDOM, K.-A. and MATSUMURA, Y. 2019. The global 
ascendency of OXA-48-type carbapenemases. Clinical Microbiology Reviews, 33, 1-48. 
RAMSAMY, Y., MLISANA, K. P., ALLAM, M., AMOAKO, D. G., ABIA, A. L., ISMAIL, A., SINGH, R., KISTEN, T., 
HAN, K. S., MUCKART, D. J. J. and ESSACK, S. Y. 2020. Genomic analysis of carbapenemase-
producing extensively drug-resistant Klebsiella pneumoniae isolates reveals the horizontal spread 
of p18-43_01 plasmid encoding blaNDM-1 in South Africa. Microorganisms, 8, 1-19. 
RUIZ-GARBAJOSA, P., HERNÁNDEZ-GARCÍA, M., BEATOBE, L., TATO, M., MÉNDEZ, M. I., GRANDAL, M., 
ARANZÁBAL, L., ALONSO, S., LÓPAZ, M. Á. and ASTRAY, J. 2016. A single-day point-prevalence 
study of faecal carriers in long-term care hospitals in Madrid (Spain) depicts a complex clonal and 
polyclonal dissemination of carbapenemase-producing Enterobacteriaceae. Journal of 
Antimicrobial Chemotherapy, 71, 348-352. 
SHEU, C.-C., CHANG, Y.-T., LIN, S.-Y., CHEN, Y.-H. and HSUEH, P.-R. 2019. Infections Caused by 
Carbapenem-Resistant Enterobacteriaceae: An update on therapeutic pptions. Frontiers in 
Microbiology, 10, 1-62. 
SOMBORO, A. M., SEKYERE, J. O., AMOAKO, D. G., ESSACK, S. Y. and BESTER, L. A. 2018. Diversity and 
proliferation of metallo-β-lactamases: a clarion call for clinically effective metallo-β-lactamase 
inhibitors. Applied and Environmental Microbiology, 84, 1-44. 
TAMMA, P. D., GOODMAN, K. E., HARRIS, A. D., TEKLE, T., ROBERTS, A., TAIWO, A. and SIMNER, P. J. 2017. 
Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-
producing carbapenem-resistant Enterobacteriaceae bacteremia. Clinical Infectious Diseases, 64, 
257-264. 
TATUSOVA, T., DICUCCIO, M., BADRETDIN, A., CHETVERNIN, V., NAWROCKI, E. P., ZASLAVSKY, L., 
LOMSADZE, A., PRUITT, K. D., BORODOVSKY, M. and OSTELL, J. 2016. NCBI prokaryotic genome 
annotation pipeline. Nucleic Acids Research, 44, 6614-6624. 
WORLD HEALTH ORGANIZATION. 2017. WHO Priority Pathogens List for R&D of New Antibiotics, [Online]. 
Available: http://www.who.int/bulletin/volumes/94/9/16-020916.pdf [Accessed 3 September 
2020]. 
WYRES, K. L. and HOLT, K. E. 2016. Klebsiella pneumoniae population genomics and antimicrobial-resistant 
clones. Trends in Microbiology, 24, 944-956. 
57 
 
XU, L., SUN, X. and MA, X. 2017. Systematic review and meta-analysis of mortality of patients infected 
with carbapenem-resistant Klebsiella pneumoniae. Annals of Clinical Microbiology and 
Antimicrobials, 16, 1-12. 
ZANKARI, E., HASMAN, H., COSENTINO, S., VESTERGAARD, M., RASMUSSEN, S., LUND, O., AARESTRUP, F. 
M. and LARSEN, M. V. 2012. Identification of acquired antimicrobial resistance genes. Journal of 
Antimicrobial Chemotherapy, 67, 2640-2644. 
58 
 
LIST OF TABLES 
Table 1. Patient demographics, antibiograms, sequence types, carbapenemase, other β-lactamases 
and ARGs in K. pneumoniae isolates. 
Table 2. Plasmid replicon types, class 1 integrons, and gene cassettes found in K. pneumoniae 
isolates. 
Table 3. ARGs and MGEs in synteny and their plasmidic/chromosomal locations. 
FIGURE LEGENDS 
Figure 1. ERIC/PCR dendrogram for CPKP isolates (n=14). Dendrogram showing isolates 
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Figure 2. Antibiotic susceptibility patterns, carbapenemase genes and plasmid replicon 
groups of CPKP isolates (n=8). Antibiotic susceptibility profiles are shown for the eight 
sequenced K. pneumonia isolates. Antibiotic resistance is displayed in red, intermediate resistance 
is displayed in yellow, and susceptibility is displayed in green. Carbapenemase genes were 
included as violet/mauve, and plasmid replicons are shown as blue. In the last column, the number 
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SUPPLEMENTAL MATERIAL: 
Table S1: Comparison of K. pneumoniae genomes with South African genomes, downloaded from 
NCBI and PATRIC servers. 
Table S2: Patients demographics. 




















































































Figure 3. Comparison E. coli plasmid p010 B-OXA181 with genome assemblies containing 





























CONCLUSIONS, LIMITATIONS AND RECOMMENDATIONS 
This study describes the molecular epidemiology of CPE colonization in patients from ICU in a 
single public hospital in the KwaZulu-Natal area using WGS and bioinformatics analysis. 
Delineating the molecular signatures of CPEs will inform containment strategies to improve 
patient outcomes. 
Conclusions 
The following conclusions were reached in relation to the objectives of the study: 
- Fourteen CPEs (14.4% of total samples) from five patients (16% of total patients enrolled) 
formed the final sample. 
- The isolates were 100% resistant to ertapenem and meropenem together with other β-
lactams, i.e., ampicillin, amoxicillin-clavulanic acid, piperacillin-tazobactam, cefuroxime, 
cefuroxime-axetil, cefoxitin, cefotaxime, ceftazidime, cefepime, ciprofloxacin, 
nitrofurantoin, and trimethoprim-sulfamethoxazole. 
- Resistance to imipenem lower at 71.4%. 
- The highest rate of susceptibility was to tigecycline and amikacin (100%), followed by 
gentamicin (85.7%). 
- All isolates were MDR displayed one of three antibiograms. 
- Five ERIC profiles were identified, with an endemic strain associated with bed 5 as evident 
from the colonization of all patients occupying this bed.  
- Bioinformatics analysis revealed that all isolates belonged to ST307. 
- ARGs identified from WGS corroborated the resistance phenotypes for all antibiotics 
except for aminoglycoside. 
- BlaOXA-181 carbapenemase carried on ISKpn19 was evident in all isolates concurrently 
with other resistance genes. 
- Other MGEs identified in the isolates included plasmid replicons, integrons (class I), and 
transposons. 
- Phylogenetic analysis clustered the isolates in clade VIII similar to isolates from Pretoria 




Limitations and Recommendations 
Limitation - The sample size was relatively small and limited to patients admitted into a general 
ICU during one month for one public hospital.  
Recommendation - To reflect the actual prevalence of CPKP in South African hospitals, future 
research should be statistically powered to include multiple study sites from different provinces. 
Limitation – Our sample was limited to carbapenemase-producing Enterobacterales and 
carbapenems resistance attributed to other mechanisms such as efflux pumps and porin profiles 
was not investigated here. 
Recommendation - Prospective studies should explore all the mechanisms contributing to 
carbapenem resistance. 
Limitation – The resistance phenomes was not corroborated with the resistomes in certain isolates. 
Recommendation – Future studies should include gene expression analysis and transcriptomics. 
Limitation – We employed short-read sequencing (Illumina MiSeq) method that precluded the 
definitive association of ARGs on MGEs. 
Recommendation - Studies in the future should use long-read third generation approaches such 
as PacBio or Nanopore SMRT sequencing to provide details about the location of ARGs 
chromosomes or plasmids. 
Further recommendations 
To prevent the colonization and spread of CPEs in ICUs in hospitals, relevant infection control 
procedures should be applied. We recommend isolating patients with verified carbapenem-
resistant Enterobacterales colonization/infection, ensuring good hand hygiene for medical staff, 
and the use of personal protective equipment together with frequent environmental 
decontamination. The implementation of active screening contact precautions for positive patients, 
decreased invasive procedures, and rational use of antibiotics for patients entering the ICU could 
further mitigate colonization and subsequent outbreaks. Regular disinfection of the environment 
and ICU equipment, frequent changes in bedding, and sterilization of medical waste from the 
patient may also significantly reduce residual bacteria in infected patients' beds. In summary, there 
76 
 
is a need for strengthening infection prevention and control policies and practices to reduce the 




Appendix 2: Additional bioinformatics analyses 
 
We further investigated assembled genomes using the Centre for Genomic Epidemiology (CGE) 
tools to determine pathogenicity, and ascertain restriction-modification systems (RMS), using 
PathogenFinder, and Restriction-ModificationFinder, respectively 
(https://cge.cbs.dtu.dk/services/PathogenFinder/, https://cge.cbs.dtu.dk/services/Restriction-
ModificationFinder/). For identifying integrative and mobilizable elements (IMEs), and prophages 









Table III: Virulence analysis of the K. pneumoniae isolates showing the virulence genes repertoire (all isolates carried the same 





Figure I (A-H): shows prophage DNA types and positions (regions) in the K. pneumonia isolates  
 

















































































































































































































































































































Figure II (A-H): Types and distribution of K and O capsule serotypes among K. pneumoniae 
 










































































































































Fig. II (H) 
 
 
 
 
 
 
 
 
 
